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Influenza pneumonitis has always been a considerable concern as it is associated with 
substantial morbidity and mortality and could lead to post-infection sequelae such as 
acute lung injury (ALI) or in more severe cases, acute respiratory distress syndrome 
(ARDS). Matrix metalloproteinases (MMPs), especially the gelatinases, contribute to 
the initial stage of ALI or ARDS pathogenesis due to their eminent ability to degrade 
major components of the basement membrane such as gelatin and collagen IV, thus 
resulting in damage of the epithelium and endothelium and consequentially, alveolar-
capillary barrier disruption. In this present study, we observed an increase in 
gelatinases MMP-2 and MMP-9 upon mouse-adapted influenza A/Aichi/2/68 (H3N2) 
P10 virus infection in a murine pneumonitis in vivo model and the acute inflammatory 
response elicited by virus infection results in massive infiltration of macrophages and 
neutrophils, which are sources of gelatinases. In addition, in vitro infection of murine 
LA-4 alveolar epithelial cells demonstrates another source of gelatinases during 
influenza virus infection. The host reponse to increase expression of gelatinases was 
accompanied by augmented epithelial and endothelial damage, as determined by 
respective elevated T1-α and thrombomodulin protein markers in the BALF and 
protein leakage into the airspaces. We show here that oral administration of a low 
dose of doxycycline, a MMP inhibitor which inhibits gelatinases MMP-2 and MMP-
9, not only reduces inflammation following influenza virus infection in mice, but also 
leads to significant assauge of host lung injury by minimising the destruction of 
pulmonary endothelium and epithelium, thus lessening leakage of proteinaceous 
 ix 
 
material into the airways. Influenza-induced host lung injury is effectively improved 
by lower doses of doxycycline but when a higher dose of the drug is administered, 
inflammation was reduced to such a substantial level that renders the viral clearance 
inefficient, resulting in high virus load which has direct cytopathic effects on the host 
cells and eventually, further pulmonary damage. It is thus vital to use a suitable 
dosage of doxycycline to reduce inflammation and gelatinase activities in influenza 
virus infection but not excessively, to alleviate host acute lung injury. There is 
currently no effective strategy for preventing influenza-induced host lung injury apart 
from the use of prophylactic influenza vaccines and anti-viral drugs. The data outlined 
in our study implicates excess MMP activity in the pathogenesis of influenza and 
doxycycline administration represents a promising therapeutic strategy by targeting 
MMPs and inflammation, for reducing immunopathology and might be an important 
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CHAPTER 1: INTRODUCTION 
Influenza A viruses pose significant public health concerns and are responsible for 
the three major influenza pandemics of the 20th century, which collectively claimed 
the lives of millions (Kumar et al, 2006). Influenza pneumonitis is associated with 
considerable morbidity and mortality, which could lead to post-infection sequelae 
such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) 
(Yokoyama et al, 2010). Polymorphonuclear neutrophils are an important component 
of the inflammatory response that characterizes ALI and ARDS as they release 
terminal effectors such as neutrophil elastases, oxygen radical species and matrix 
metalloproteinases during influenza virus infection which consequentially leads to 
damage of both pulmonary endothelium and epithelium (Fingleton, 2007; Quispe-
Laime et al, 2010). The disruption of the capillary-alveolar barrier function results in 
the leakage of inflammatory exudates, edema fluid and plasma proteins into the lung 
interstitium and alveolar spaces and the collapse of the alveoli leads to impaired 
gaseous exchange in the lung (Bdeir et al, 2010; Fingleton, 2007). Matrix 
metalloproteinases (MMPs), especially the gelatinases, contribute to the initial stage 
of ALI or ARDS pathogenesis due to their eminent ability to degrade major 
components of the basement membrane such as gelatin and collagen IV, contributing 
to damage of the epithelium and endothelium (O‘Connor and FitzGerald, 1994).  
 
Gelatinases MMP-2 and MMP-9 have been implicated in many pathological 
conditions including cancer, cardiovascular diseases and a range of pulmonary 
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injuries including ARDS, fibrosis and emphysema (Rundhaug, 2003; Malemud, 
2006; O‘Connor and FitzGerald, 1994). In recent years, the research of influenza 
viruses and MMPs has become more extensive. Yeo et al, 1999 demonstrated the 
effect of influenza A/Beijing/353/89 (H3N2) virus infection on the expressions of 
MMP-2 and -9 in two epithelial cell lines: Vero cells and Madin-Darby Canine 
Kidney (MDCK) cells while clinical studies showed an increase in MMP-9 levels in 
patients with influenza-associated encephalopathy (Ichiyama et al  ¸ 2007). In a most 
recent study, authors have suggested a possible role of MMP-9 in pulmonary 
pathology and multiple organ failure during influenza virus infection (Wang et al, 
2010).  
 
Despite their characterized role in various pulmonary pathological processes, the 
mode of regulation and modulation of gelatinases after influenza virus infection in a 
pneumonitis murine model still remains unclear. Previous work in our lab had 
established a mouse adaptation model through serial lung-to-lung passaging, of which 
the mouse-adapted influenza A/Aichi/2/68 (H3N2) virus, also known as P10 virus, 
caused severe pneumonitis and broad tissue tropism in the host (Narasaraju et al, 
2009). Transcriptomic analysis of severe murine pneumonitis induced by this mouse-
adapted P10 virus, using microarray and real-time quantitative PCR, revealed an 
upregulation in gene expression of members of the MMP family, including MMP-3, 
MMP-8, MMP-9, MMP-13 and MMP-14, a protein involved in activation of MMP-2, 
at the 96h post-infection timepoint (Unpublished data). In view of the fact that 
gelatinases MMP-2 and MMP-9 from inflammatory cells may aid the destruction of 
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the integrity of basement membrane of the epithelium and endothelium, which might 
result in host lung injury such as ALI or ARDS during influenza virus infection, one 
of the aims of the present study is to investigate the effect of the mouse-adapted 
influenza A/Aichi/2/68 (H3N2) P10 virus on the protein expression of these 
gelatinases, MMP-2 and MMP-9, in an in vivo murine model. Influenza virus 
infection of an in vitro murine alveolar epithelial LA-4 cell line would also provide 
clues to a possible source of gelatinases besides the inflammatory cells during viral 
infection.  
 
Another objective of the current study is to conduct an investigation into the possible 
role of an MMP inhibitor in ameliorating damage and immunopathology associated 
with Influenza A infection. This is in light of current evidence that MMPs, 
particularly MMP-9, are terminal effectors released by neutrophils and have been 
proven to be involved in pulmonary immunopathology which might lead to 
development of emphysema and ALI or ARDS, fatal consequences of influenza virus 
infection. Doxycycline has been reported to have protective actions via their MMP 
inhibitory actions in various pulmonary conditions such as toluene diisocyanate 
induced asthma, lipopolysaccharide-induced acute lung injury and pulmonary fibrosis. 
These were accompanied by a decrease in gelatinase expression (Fujita et al, 2006; 
Fujita et al, 2007; Lee et al, 2004; Liu et al  ¸ 2006). Since the prophylactic 
administration of doxycycline hyclate has been shown to reduce inflammation and 
pulmonary damage in lung injury models and it is such a well-studied potent MMP 
inhibitor and is commercially available in the market with well tolerable side effects, 
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we have chosen to use it in our study to research its effectiveness in alleviating 
influenza virus-induced host lung injury. The findings of this investigation will thus 
shed light on a possible therapeutic candidate in preventing post-infection sequelae 
such as pulmonary damage, especially in the light of the most recent influenza 
pandemic. Such a study would serve a relevant purpose where the threat of a massive 
pandemic from possible highly pathogenic avian Influenza virus looms over the 
horizon, where such a treatment could supplement use of existing anti-viral drugs and 
prevent excessive morbidity and mortality from influenza infections in the pre-

















CHAPTER 2: SURVEY OF LITERATURE 
2.1 Background of Influenza Virus 
Influenza, commonly known as the flu, is an acute infectious disease that has been 
causing substantial mortality and morbidity over vast geographical distributions for 
the past century, leading to huge socio-economic burden. The influenza virus is an 
enveloped, multi-segmented, single-stranded, RNA genome, with negative polarity, 
that belongs to the Orthomyxoviridae family (Plakokefalos et al, 2001). Based on the 
differences in internal antigens, namely the nucleocapsid proteins and matrix proteins, 
influenza viruses are classified as type A, B or C (Margaret Hunt et al, 2006). Type A 
and B influenza viruses contain eight gene segments, consisting of Hemagglutinin 
(HA), Neuraminidase (NA), Non-structural (NS), Matrix (M), Nucleoprotein (NP), 
the polymerase genes PA, PB1 and PB2, which encode for eleven proteins, while 
Influenza C viruses harbor only seven genome segments (Gürtler, 2006). The 
antigenicity of the HA and NA surface proteins determine the subtypes of influenza 
viruses (Yuki et al, 2009). Major outbreaks of influenza are associated with types A 
and B viruses while type C virus is usually only associated with minor symptoms. Of 
the three, influenza A virus is of the greatest concern as it is the major cause of global 






2.2 Influenza Pathogenesis  
The Influenza virus gains entry to host cells through its surface glycoprotein HA. HA 
in Influenza viruses is crucial in the viral pathogenesis process with its glycosylated 
HA0 molecule being cleaved by cellular proteases to HA1 and HA2. These two HA 
segments are linked by a disulphide-bridge, with the HA1 domain containing the 
receptor binding site. This surface HA1 molecule recognizes and binds sialic acid 
(SA) residues on the surface of host cells in the early stages of infection. After 
binding the SA residues, HA2 then mediates fusion of the host endosomal membrane 
with the viral membrane, allowing entry of the viral genome into the host cell. Human 
influenza viruses recognize SA containing receptors which possess α-2,6 galactose 
linkages. Avian influenza viruses such as Avian Influenza H5N1 recognize α-2,3 SA 
containing receptors, which is also the case for mice Influenza viruses. Once the virus 
has successfully invaded the host cell, it would proceed to reverse transcribe its viral 
RNA genome and replicate inside the host cell nucleus. Viral RNA would also be 
transported to the cytoplasm of the host cell for protein synthesis. The HA and NA 
molecules then cluster and aggregate at the projection in the host cell membrane as 
the virus particles are budding off from the host cell, taking along the host cell 
membrane, which constitutes the virus particle envelope.  
 
2.3  Occurrence and geographical distribution 
According to a report by World Health Organization, there are 3 to 5 million severe 
influenza cases and 250,000 to 500,000 mortality every year (Kamps and Reyes-
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Terán, 2006). Three major influenza A pandemics occurred during the 20
th 
century 
(Kumar et al, 2006). One classical tragic example was that of the 1918 Spanish flu, 
caused by the Influenza A H1N1 subtype virus, which killed at least 50 million people 
worldwide. Europe, Asia and North America were the hardest hit during that period 
(Kamps and Reyes-Terán, 2006). The second pandemic was the ―Asian flu‖, caused 
by H2N2. Its occurrence was in 1957 and it spread from China to United States 
(Kumar et al, 2006). The third influenza strain pandemic occurrence was the 1968 
―Hong Kong flu‖, caused by the H3N2 subtype virus, which killed around 1 million 
people across Europe, Asia and United States (Viboud et al, 2005; Kamps and Reyes-
Terán, 2006). The most recent ―Swine flu‖ pandemic was in 2009, involving a H1N1 
reassortment virus, which led to at least 10,000 deaths (WHO, 2010). Prior to the 
emergence of the 2009 H1N1 swine flu, a H5N1 subtype virus has been regarded as a 
potential pandemic candidate as it is responsible for case reports in numerous 
countries, including Asia, Southeast Asia, Europe and Africa as well (Kamps and 
Reyes-Terán, 2006). This H5N1 virus strain is still circulating among the population 
and the most recent human infection cases in 2010 are reported in Indonesia and 
Egypt (WHO, 2010). 
 
2.4 Clinical Pathology of Influenza virus 
The influenza A virus can infect multiple species, including humans, mammals and 
birds (Coiras et al, 2001). Replication of the virus is limited to epithelial cells of the 
respiratory tract (eg. nose, bronchi and alveoli) and the host cells die due to either the 
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direct effects of the virus on bronchiolar and alveolar cells, or by host hyper immune 
response (Margaret Hunt et al, 2006). The latter occurs when the infected host 
generates intense inflammatory cytokines which will lead to excessive infiltration of 
inflammatory cells such as macrophages and polymorphonuclear neutrophils, and 
consequentially severe inflammation and epithelial damage (Sakai et al, 2000). The 
clinical symptoms of influenza can range from minor sore throats, fever, to severe 
complications such as primary viral pneumonia or secondary respiratory bacterial 
infections, resulting in death (Zambon, 1999; Kamps and Reyes-Terán, 2006). Acute 
infections of Influenza A virus can lead to multifocal destruction and desquamation of 
the pseudostratified columnar epithelium of the trachea and bronchi, in which 
significant edema and congestion occurs in submucosal spaces of the upper 
respiratory tract. In the bronchiole-alveolar junctions, there is massive necrotic cell 
death of the epithelial cells, accompanied by congestion caused by inflammatory 
infiltrates (Taubenberger and Morens 2008). In more severe cases, acute lung injury 
(ALI) develops, displaying diffused alveolar damage and edema, and it could develop 
into a more severe form known as Acute Respiratory Distress Syndrome (ARDS), in 
which infected subjects die due to the impaired physiological function of the lung 
(Quispe-Laime et al, 2010; Takiyama et al, 2010; Yokoyama et al, 2010). 
 
2.5 Influenza virus and host defences 
During an acute influenza virus infection, both arms of immunity: Innate and 
adaptive, are important in protecting the host against the pathogen. The former has a 
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primary goal of limiting virus growth and activating the onset of the adaptive arm, in 
which viral clearance takes place (Tate et al, 2008). In the early innate phase of host 
defence, natural killer (NK) cells, dendritic cells, macrophages and neutrophils are 
activated and recruited to the airways. Pulmonary macrophages consist of the majority 
of phagocytes present in the respiratory tract and they function as the chief scavenger 
cells, due to their ability to phagocytose both influenza virus-infected cells and 
antibody-opsonized influenza virus particles, contributing to viral clearance (Reading 
et al, 2010; Sibille, 1990; Wells et al, 1978). The macrophages also secrete 
proinflammatory cytokines and chemokines such as interferon α and β, tumor necrosis 
factor α and CC chemokines, resulting in more intensive pulmonary inflammation 
(Kim et al, 2008; Tumpey et al, 2005). Neutrophils, on the other hand, are present in 
small numbers in the respiratory tract and are more recognized as key protective 
players against bacteria and fungal infection. However, these polymorphonuclear 
leukocytes have also been regarded as an essential tool of defence against viral 
infections such as influenza virus and herpes simplex virus type 1 (Smith, 1994; 
Tumpey et al, 2005). According to Tate et al, 2009, neutrophil infiltration in the early 
phases of influenza virus infection is a characteristic feature, in which these 
leukocytes play a vital role in limiting viral replication (Sweet and Smith, 1980). 
Fujisawa 2008 demonstrates the role of neutrophils in inhibiting influenza virus 
multiplication in vitro while Fujisawa et al, 1987 shows that these polymorphonuclear 
leukocytes are capable of phagocytosing the influenza virus itself. Neutrophils also 
have the ability to kill apoptotic influenza virus-infected cells via cellular cytotoxicity 
reactions in the presence of antibodies or complements (Hashimoto et al, 2007; 
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Ratcliffe et al,1988). Since neutrophils are not permissive to influenza virus infection, 
unlike the macrophages, they are important in eliminating the virus when the infected 
macrophages are non-functional (Fujisawa, 2001).  
 
Following the roles of the innate immunity in partially reducing the virus load, 
recovery from influenza virus infection is dependant on the T and B lymphocytes 
(Tumpey et al, 2005). This phase of host defence is essential for viral clearance as the 
CD8+ T cells, CD4+ T cells and the B cells work in concert to remove the pathogen. 
The CD8+ cytotoxic lymphocytes recognize influenza virus-infected cells which 
display fragments of the viral proteins in their surface class I major histocompatibility 
molecules (MHC I) and mediate cytolysis of the infected cells via the release of 
antiviral cytokines such as interferon-γ, tumour necrosis factors and perforins (Chen 
and Deng, 2009; Schmolke and Garcia-Sastre, 2010; Subbarao and Tomy Joseph, 
2007). The CD4+ T cells bind to epitopes presented by antigen presenting cells such 
as macrophages or dendritic cells consisting of fragments of the viral proteins in their 
MHC II molecules, and release lymphokines to attract more immune cells to the site 
of injury to destroy the antigenic material. CD4+ cells, also known as helper T cells, 
also bind to antigens presented by B cells to aid in the production of antibodies 
against the virus, to ensure elimination of the pathogen in future infections (Doherty 






2.6 Neutrophils  
Neutrophils, also known as polymorphonuclear leukocytes, is abundant in the blood 
circulation and represent 50 to 60% of the total circulating leukocytes. However, they 
are scarce in the respiratory tract during normal physiological conditions. During an 
influenza virus infection event, chemoattractants including interleukin 8 (IL-8) are 
secreted from macrophages and will bind to the CXC receptors located on the 
neutrophils to stimulate their recruitment from the blood vessels to the pulmonary 
airways, to aid in the elimination of the foreign pathogen (Appelberg, 2007; Gaggar et 
al, 2008). The process of neutrophil extravasation and recruitment into the pulmonary 
airways is depicted in figure 2.1. Neutrophils exit the circulation in a series of steps: 
Tethering, rolling, modulation of adhesion strength, intraluminal crawling and 
transcellular and paracellular migration (Zemans et al, 2009). The neutrophils are 
captured to the endothelial surface via interactions between L, E and P-selectins and 
P-selectin glycoprotein ligand (PSGL1) and VLA4 integrin, prior to the rolling of the 
leukocytes along the endothelium. Secretory vesicles containing a group of 
membrane-associated receptors will then be mobilized and incorporate proteins such 
as β2 integrins: CD11b and CD18 into the neutrophil plasma membrane to facilitate 
stronger adhesion to the blood vessel (Faurschou and Borregaard, 2003). This is 
followed by the release of gelatinases from neutrophilic tertiary granules, which are 
activated by neutrophilic elastases, and aids in type IV collagen degradation in 
basement membrane, and subsequentially the migration of the leukocyte across the 
endothelium (Delclaux et al, 1996). The neutrophils then move through the 
extracellular matrix (ECM) along fibroblasts to reach the epithelium (Downey et al, 
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2009). Neutrophil migration across the pulmonary epithelium is facilitated once again 
by gelatinase degradation of epithelial basement membrane and also occurs in 
sequential stages: Adhesion, migration and postmigration. The neutrophils adhere to 
the basolateral surface of the epithelial cells via β2 integrin, intercellular cell adhesion 
molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1) and other adhesive 
molecules interaction and the cells migrate across in a paracellular route. This is 
followed by the adherence of the leukocytes to the apical surface of the pulmonary 
epithelium, in which they can carry out their antimicrobial activities in the airspaces 
(Borregaard and Cowland; 1997; Zemans et al, 2009). 
 
There are three types of neutrophilic cytosolic granules – Azurophil or Primary 
granules, Specific or Secondary granules, and Gelatinase or Tertiary granules. The 
contents of the various types of granules are summarized in table 2.1. The azurophilic 
granules constitute mainly the antimicrobial peptides that are released into the 
phagolysosome and these include cationic peptides such as defensins, degradative 
enzymes such as myeloperoxidases (MPO), and serine proteases including elastases, 
cathepsin G and proteinase 3 (Smith 1994; Segal, 2005). The specific granules contain 
lysozymes, lactoferrin and cathelicidin, which have antimicrobial properties. Lastly, 
the tertiary granules encompass gelatinases, in particular MMP-9, which were 
mentioned earlier in this section and will be discussed in greater detail in section 2.9 
(Segal, 2005). Upon influenza virus infection, neutrophil effector systems are 
mobilized and the virus or virus-infected cells are engulfed and phagocytosed to form 
a lysosome within the neutrophil (Witko-Sarsat et al, 2000). This engulfment 
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activates the neutrophil and it undergoes respiratory burst, which involves the rapid 
increase in oxygen consumption to generate reactive oxygen species. The neutrophils 
also release the contents from their cytosolic primary and secondary granules into the 
phagolysosome, creating a highly toxic microenvironment which kills the virus or 
infected host cells. These short-lived leukocytes eventually undergo apoptosis and are 
engulfed by macrophages, in which their contents are degraded (Appelberg, 2007; 







































Figure 2.1. The extravasation process of neutrophils into the respiratory airways 
during infection. (1) Contact of the neutrophils to the endothelial surface is mediated 
by selectin molecules (green and pink), causing the neutrophils to roll along the 
endothelium (2) Further strong adhesion to blood vessel wall is mediated by activated 
β2 integrins (red) (3) Migration between endothelial cells is facilitated by the release 
of gelatinases from neutrophilic tertiary granules, which aids in type IV collagen 
degradation in basement membrane (4) Migration through ECM occurs along 
fibroblasts (5) Migration through alveolar epithelial cells uses CD47-signal regulatory 
protein α (yellow) (6) Tethering to apical surface of alveolar epithelial cells through 
β2 integrins and intercellular adhesion molecule 1 (ICAM-1) (red)  (Adapted from 
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2.7 Neutrophils and Influenza virus-induced lung injury 
As mentioned in section 2.4, neutrophils are part of the innate immunity and comprise 
of the first line of defence against influenza viruses. However, these leukocytes 
exhibit another spectrum of activities, in which they have been implicated in host 
tissue damage and the pathology of many diseases, including acute lung injury during 
influenza virus infection, ischemia-reperfusion injury such as myocardial ischemia, 
tumor development, rheumatoid arthritis, septicaemia with multiorgan failure and 
chronic Pseudomonas bacterial pulmonary damage (Weitzman and Gordon, 1990; 
Ras et al, 1992; Edwards and Hallett, 1997; Witko-Sarsat et al, 2000; Mahmudi-Azer 
and Eeden, 2003).  
 
Polymorphonuclear neutrophils are an important component of the inflammatory 
response that characterizes ALI and ARDS during influenza virus infection 
(Abraham, 2003; Fingleton, 2007; Martin, 2002; Quispe-Laime et al, 2010). The 
pathogenesis of ALI and ARDS is depicted in figure 2.2, adapted from Ware and 
Matthay, 2000. ALI is a complex clinical syndrome that is characterized by 
noncardiogenic pulmonary edema, capillary leakage and pneumonia. The most severe 
form of ALI is ARDS, which is characterized by diffused leukocyte inflammation of 
the lung parenchyma, diffused alveolar damage, epithelial injury, pulmonary 
haemorrhage, hypoxemia and sometimes multiple organ failure (Bdeir et al, 2010; 
Crowe et al, 2009; Rubenfeld et al, 2005; Xu et al, 2006). A paradigm of 
inflammatory cascade results in ARDS. ARDS comprises of classically three phases: 
exudative, proliferative and fibrotic. In the early exudative phase, proinflammatory 
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initiators from monocytes, vascular endothelial cells and alveolar macrophages are 
released, resulting in sequestration and migration of neutrophils. The activated 
neutrophils release terminal effectors such as neutrophil elastases, matrix 
metalloproteinases and oxygen radical species which injure the lung tissues, thus 
leading to leakage of proteinaceous fluid into the alveolar space and airways. The 
intense inflammatory response leads to damage in both pulmonary endothelial and 
epithelial cells, and the disruption of the capillary-alveolar barrier function results in 
the leakage of inflammatory exudates, edema fluid and plasma proteins into the lung 
interstitial and alveolar spaces. The loss of epithelial integrity also has severe 
consequences. The injury to epithelial cells contributes to alveolar flooding, reduces 
production of surfactant and impair epithelial repair processes which could lead to 
fibrosis. The pulmonary edema that results, thickens the alveolo-capillary space and 
might cause collapse of the alveoli. This compromises the lung‘s normal 
physiological function and impair gaseous exchange in the lung. In the proliferative 
and fibrotic stages, fibroblasts and type II pneumocytes show increased proliferation 
and the fibroblasts secrete ECM proteins both within the interstitium and out into the 
alveolar space, thus causing excessive deposition of collagens in the fibrotic stage 
which results in airway blockage (Bdeir et al, 2010; Downey et al, 1999; Fingleton, 
2007; Ware and Matthay, 2000).  
 
ALI and ARDS are serious complications of influenza virus infection and are 
common causes of morbidity and mortality globally (Davidson et al, 1999; Matthay et 
al, 2003; Yokoyama et al, 2010). During the 2009 H1N1 ―Swine flu‖ influenza A 
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virus pandemic, some patients developed severe pneumonia and ARDS which 
resulted in prolonged intensive care unit stay and death (Dawood et al, 2009; 
Domınguez-Cherit et al, 2009; Kumar et al, 2009; Perez-Padilla et al, 2009; Rello et 
al, 2009). Yokoyama et al, 2010 reported that in a severe ARDS condition due to 
H1N1 influenza viral infection, the patient showed neutrophilic infiltrate, diffused 
alveolar damage and haemorrhage. Bellani et al, 2010 also described an exceptionally 
high number of activated neutrophils in a patient that developed pneumonia and 
eventually ARDS, upon ―Swine flu‖ infection. Several other studies also observed 
that H5N1 infected patients display severe lung pathology characteristic of ARDS, 
suggesting that ARDS might be one of primary reasons for patients death (Grose and 
Chokephaibulkit, 2004; Tran et al, 2004). In patients whom developed ARDS during 
H5N1 infection, a neutrophil chemoattractant, interleukin-8 (IL-8) was elevated, 
which suggests greater neutrophil infiltration (Peiris et al, 2007). Furthermore, in a 
H5N1 infection in vivo murine model, mice infected with Chicken/HB/108 H5N1 
virus presented severe bronchiolitis, bronchopneumonia and hypoxemia, which was 
consistent with the pulmonary lesions of ARDS. This was accompanied by a 26-fold 
of neutrophils in their bronchoalveolar lavage fluid (BALF) (Xu et al, 2006). Thus, 
excessive neutrophil-associated proteolytic activity is a major contributing factor to 
the pathogenesis of ALI and ARDS. 
 
Neutrophil-predominant host inflammatory response is thus essential for the 
development of ALI and ARDS and the migration of neutrophils into the lungs is 
central to the pathogenesis (Xu et al, 2006). Neutrophil cytosolic granules contain 
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proteolytic enzymes which can eliminate microbial pathogens and these proteins are 
released directly into the phagolysosome where the pathogen is compartmentalized, as 
mentioned briefly in section 2.5. However, when these antimicrobial products are 
inappropriately released into the extracellular space, they can cause indiscriminate 
destruction to host tissues. Neutrophil-mediated tissue damage occurs when 
neutrophils are excessive or unregulated and when there is premature activation 
during migration. Failure to terminate acute inflammatory neutrophilic responses can 
also lead to host tissue destruction (Smith 1994). During the migration of neutrophils 
from the vascular bed to the airways in the infected lung, described in section 2.5, 
unrestrained activation of neutrophils could occur in response to microbial or host-
derived stimuli, and excessive release of the proteolytic enzymes will damage and 
slough off the pulmonary epithelial and endothelial cells. The damaged endothelium 
and epithelium then results in ALI and ARDS (Zemans et al, 2009).  
 
2.8 Neutrophilic Enzymes 
Neutrophils have an abundance of proteins stored in their cytosolic granules, as 
reviewed in table 2.1. Many of these proteins are enzymes which are released upon 
neutrophil activation, and they participate in antimicrobial processes including 
neutrophil extravasation and pathogen elimination. Paradoxically, they are also 
integral in pathological processes including the development of ALI and ARDS 
during influenza virus infection, when their secretion is uncontrolled. Examples of 
such neutrophilic enzymes include myeloperoxidase (MPO), elastases and matrix 
metalloproteinases (MMP).  
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Figure 2.2. The normal alveolus (Left-hand side) and the injured alveolus in the 
acute phase of Acute lung injury and the Acute respiratory distress syndrome 
(Right-hand side). In the acute phase of ALI or ARDS, there is sloughing of 
bronchial and alveolar epithelial cells. Neutrophils adhere to the injured capillary 
endothelium and migrate through the interstitium into the air space, which is filled 
with protein-rich edema fluid. In the air space, an alveolar macrophage secretes 
cytokines, interleukin-1, 6, 8 and 10 (IL-1, 6, 8 and 10) and tumor necrosis factor 
(TNF-α), which act locally to stimulate chemotaxis and activate neutrophils. IL-1 also 
stimulates production of extracellular matrix by fibroblasts. Neutrophils can release 
oxidants, proteases, leukotrienes and other proinflammatory molecules such has 
platelet-activating factor (PAF). Widened edematous interstitium results and the 
influx of protein-rich edema fluid into the alveolus leads to the inactivation of 





Reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an 





is converted to hydrogen peroxide (H2O2) via the action of 
superoxide dismutase (Babior et al, 2002). The release of reactive oxygen species, O2
-
 
and H2O2, within the neutrophils is through a phenomenon known as respiratory burst, 
characterized by a massive increase in oxygen consumption (Quinn and Gauss, 2004; 
Takanaka and O‘Brien, 1975). Myeloperoxidase, a haem protein found in the 
azurophil granules of neutrophils, then converts the H2O2 into hypochlorous acid 
(HOCl) (Hazen et al, 1996). HOCl is a neutrophil specific oxidant and though it is a 
non-radical species, it can react with H2O2 and O2
-
 to produce other oxidant radicals 
such as hydroxyl radical (OH) (Wahn et al, 2002). Nitric oxide synthase (NOS) can 
also catalyse O2
-
 into reactive nitrogen species such as nitric oxide (NO) and 
peroxynitrite (ONOO
-
). The whole process is summarized in figure 2.3. Though the 
generation of these reactive oxygen and nitrogen species are important in eliminating 
the pathogen during influenza virus infection of the host, ALI or ARDS can result 
when the oxidants are generated in excess of antioxidant defences (Lang et al, 2002). 
Akaike et al, 1990 and Oda et al, 1989 report superoxide anions to be the primary 
pathogenic molecules in influenza virus-induced pneumonia and lung injury in mice 
and when these anions are removed from the system, therapeutic consequences result. 
Furthermore, influenza virus-induced lung pathology in mice has been correlated with 
the increased expression of NOS and increased production of NO and survival of 






Figure 2.3. Oxidant generating reactions with activated neutrophils for 
antimicrobial effect during an infection event. NADPH oxidase generates reactive 
oxygen species, superoxide anion, O2
-
, from NADPH and oxygen. Superoxide 
dismutase then converts the O2
-
 into H2O2. Myeloperoxidase (MPO) catalyses the 
conversion of H2O2 to HOCl, which can react with H2O2 and O2
-
 to generate more 
reactive oxygen species. Nitric oxide synthase (NOS) generates reactive nitrogen 
species such as nitric oxide (NO) and peroxynitrite (ONOO
-
) from superoxide anion, 
O2
-





Neutrophil elastases are serine proteases which are present in high concentrations in 
the azurophil granules and have a role in both host defence and pulmonary disease 
progression. These enzymes degrade extracellular matrix (ECM) components 
including elastin, type I to IV collagen, fibronection and laminin, thus facilitating the 
migration of neutrophils from the blood circulation to the airspaces through the cells 
and ECM (Lungarella et al, 2008). Hence, neutrophil elastases are involved in the 
elimination of influenza virus and the virus infected apoptotic cells via the recruitment 
of neutrophils to infected site and the generation of O2
-
 (Gao et al, 2002; Shapiro, 
2002). However, this role of neutrophil elastases in neutrophil recruitment is still 
controversial and yet to be clearly determined (Foong et al, 2010). Nevertheless, the 
implication of neutrophil elastases in the pathology of several lung conditions 
including pulmonary emphysema, ALI and ARDS has already been widely illustrated 
(Lee and Downey, 2001; Shapiro et al, 2003). Killackey and Killackey, 1990 
demonstrated that elastase levels were directly proportional to vascular permeability 
in ARDS while Lee et al, 1981 observed the elevated amounts of neutrophil elastase 
in BALF of ARDS patients. Carden et al, 1998 also reported the elastase-mediated 
proteolysis of endothelial cadherins which results in disruption of the microvascular 
barrier integrity in ARDS. Another vital function of neutrophil elastase is its ability to 
activate one member of the matrix metalloproteinase (MMP) family, MMP-9, which 





2.9 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs), also known as matrixins, are members of the 
metzincin superfamily, along with astacins, reprolysins (ADAMs) and serralysins. 
This superfamily is distinguished by a conserved methionine turn beneath the active 
site zinc ion and a highly conserved zinc-binding motif of HEBXHXBGBXHZ within 
the catalytic domain, where histidine (H), glutamic acid (E) and glycine (G) residues 
are invariant, B is a bulky hydrophobic residue, X is a variable residue and Z is a 
family-specific amino acid (Sternlicht and Werb, 2001). In the MMP family, all 
members contain two conserved motifs, namely the pro-domain and the catalytic 
domain, with the former possessing a conserved cysteine residue which will bind to 
the zinc ion in the active site located in the catalytic domain, to render the propeptide 
inactive. The only exception is MMP-23, in which the cysteine residue is found in a 
distinct amino acid sequence (Parks and Shapiro, 2000). A calcium ion is also present 
in the catalytic domain to render stability to the MMP structure (Massova et al, 1998). 
In addition to the two conserved regions, all MMPs also have a proline-rich hinge 
region and a carboxy terminal hemopexin-like domain which participates in substrate 
recognition and interaction with tissue inhibitors of metalloproteinases (TIMPs). 
MMPs can be either secreted extracellularly or membrane bound and the latter has 
transmembrane (TM) domains or glycosylphosphatidyl-inositol (GPI) anchors 
attached to the hemopexin-like domains to facilitate binding to the cell membrane 
(Parks et al, 2004; Stamenkovic 2003; Sternlicht and Werb, 2001). Figure 2.4 depicts 
the domain structures of the structural subclasses of MMP. With 25 vertebrate MMPs 


























Figure 2.4. Domain structure of MMPs. The principal structural subclasses of MMPs are shown and important features of MMPs are 
illustrated, showing the minimal domain structures. All members possess a signal peptide (SP), pro-domain (Pro), which contains a zinc ligating 
thiol (–SH) group,  and catalytic domain, which contains a zinc ion (Zn2+). Hemopexin-like domains are essential in binding to tissue inhibitors 
of metalloproteinases (TIMPs). Membrane-anchored MMPs have transmembrane (TM) domains or glycosylphosphatidyl-inositol (GPI) anchors 
attached to facilitate binding to the cell membrane. Gelatin binding MMPs have fibronectin repeats (Fn) which are essentially gelatin binding 








Figure 2.5. Classification of members of the MMP family. MMPs are categorized 
into six groups based on their sequence similarity, domain organization and substrate 
specificity. These six groups include collagenases, gelatinases, stromelysins, 
matrilysins, transmembrane MMPs (MT-MMPs) and others. (Adapted from Snoek-









substrate specificity, sequence similarity and domain organization. These six groups 
include collagenases, gelatinases, stromelysins, matrilysins, membrane type MMPs 
(MT-MMPs) and others (Parks et al, 2004; Stamenkovic 2003; Sternlicht and Werb, 
2001). Figure 2.5 shows the general classification of the members in the MMP family. 
Collagenases comprise of MMP-1, MMP-8 and MMP-13 and they can cleave 
primarily interstitial collagens I, II and III. Gelatinases include gelatinase A (MMP-2) 
and gelatinase B (MMP-9), which contain fibronectin repeats within the catalytic 
domain to facilitate binding to their main substrates type IV collagen and gelatin, a 
product of denatured collagen. In addition, MMP-2 can also digest type I, II and III 
collagens while MMP-9 can digest type V collagen. Elastin and laminin have also 
been proven to be substrates of both gelatinases as well (McMillan et al, 1995; Visse 
and Nagase, 2003). Stromelysins include MMP-3, MMP-10 and MMP-11 and besides 
digesting ECM components such as fibronectin and collagen IV, these enzymes can 
also activate some pro-MMP zymogens. Matrilysins such as MMP-7 and MMP-26 
lack the hemopexin-like domain and can digest gelatin and fibronection. Lastly, the 
six-membered group of MT-MMPs can digest ECM proteins such as gelatin, 
fibronectin and laminin and also has the ability to activate pro-MMP-2. The 
remaining MMPs are gathered in a more heterogeneous subgroup with various 
substrates (Snoek-van Beurden and Von den Hoff, 2005; Visse and Nagase, 2003). 
 
MMPs are synthesized and secreted extracellularly in a latent proenzyme form and 
disruption of the bond between the zinc ion in the active site and the cysteine residue 
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in the propeptide domain is essential to initiate the stepwise MMP activation process. 
This mechanism is referred to as the ―cysteine switch‖. The noncatalytic zinc is 
switched to a catalytic one, resulting in an intermediate active enzyme. Full activation 
of MMPs is subsequently achieved by either autolytic cleavage or proteolysis by other 
proteases (O‘Connor and FitzGerald, 1994; Stamenkovic, 2003). The MMP activation 
process is depicted in figure 2.6. Several pro-MMPs contain a RXKR or RRKR 
sequence between the propeptide and catalytic domains which function as a target 
sequence for serine proteases such as furins while other pro-MMP members can be 
activated by fellow MMPs which have been activated earlier. One of the best 
described non-furin pro-MMP activation mechanism is the cell surface activation of 
pro-MMP2 by active MMP-14 (Parks et al, 2004). Trypsin, plasmin, urokinase type 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), among 
others, were also implicated as important physiological activators of MMPs (Mignatti 
and Rifkin, 1993). Furthermore, oxidants such as hypoclorous acid (HOCl) generated 
by leukocytes have been suggested a role in MMP activation, through the oxidation of 
the thiol group in the propeptide domain (Fu et al, 2001; Peppin and Weiss, 1986; 
Weiss et al, 1985). 
 
The most common knowledge of MMP proteins is their imperative and direct role in 
extracellular matrix (ECM) degradation. The ECM is an extracellular scaffold which 
not only provides mechanical support to the cells, but also plays a role in many 
cellular functions. Thus, the interaction of cells with the ECM is critical for the 




































Figure 2.6. “Cysteine Switch” mechanism for the activation of matrix 
metalloproteinases. The bond between the zinc ion in the active site and cysteine 
residue in the thiol group located in the propetide domain is disrupted, leading to a 
conformational change. This can be due to physical agents such as sodium dodecyl 
sulfate (SDS) or chaotropic agents that can expose the zinc and allowing reagents 
such as oxidized glutathione (GSSG), aminophenyl mercuric acetate (APMA) and 
hypochlorous acid (HOCl) to inactivate the cysteine (Left). Alternatively, proteolytic 
enzymes such as trypsin, furin or plasmin can cleave the propeptide (Right). The 
partially active enzyme is then fully activated by either autolytic cleavage or other 
MMPs to remove the propeptide and confer permanent activity. (Adapted from 





is a reservoir of matrix molecules which includes signaling molecules such as growth 
factors and growth factor-binding proteins that are ligands for receptors such as 
integrins and can transmit signals to the cell interior. These complex signaling 
processes help to regulate cell proliferation, growth, differentiation and death by 
controlling cell adhesion and cytoskeletal machinery (Järveläinen et al, 2009; Parks et 
al, 1994; Teti, 1992). ECM degradation by MMPs is essential in normal physiological 
processes involving ECM turnover and tissue remodeling, such as embryonic 
development, collagen turnover, cell migration and wound healing (Chin and Werb, 
1997; Heikinheimo and Salo, 1995; Pilcher et al, 1999). The function of MMPs, 
however, extends beyond that of ECM degradation and being enzymes, MMPs have a 
huge array of non-ECM proteins as their substrates, thus abolishing their normal 
biologic function and generating breakdown products with entirely new biologic 
activities (Sternlicht and Werb, 2001; Visse and Nagase, 2003). MMPs affect cell 
proliferation by cleaving growth factors which are non-matrix protein associated. 
Heparin-binding epidermal growth factor (HB-EGF) has been reported to be a 
substrate for MMP-3 and gelatinases have been shown to process transforming 
growth factor β (TGF-β), tumor necrosis factor (TNF) and interleukin-1β (IL-1β) into 
their active form, both being involved in inflammatory processes. In the modulation 
of cell death and cell migration, MMPs cleave the Fas ligand and enable it to bind to 
the Fas receptor to elicit apoptosis, and also aids in the release of vascular endothelial 
growth factor (VEGF) which acts as a chemoattractant for osteoblast recruitment 




Since the MMPs are key players in the degradation of integral ECM components and 
possess such a wide range of biological functions, they have to be tightly regulated. 
This is achieved at four points: Gene expression, zymogen activation, enzyme 
inactivation and compartmentalization (Parks et al, 2004). Typically, most MMPs are 
not synthesized until needed and are inducibly transcribed, with the exception of 
MMP-2, which is constitutively expressed. Thus, MMP production is primarily 
regulated at the transcriptional level by specific signals, elicited by growth factors and 
cytokines, that are temporally limited and confined. In addition, MMP mRNA 
stability is also modulated in response to growth factors and cytokines (Snoek-van 
Beurden and Von den Hoff, 2005; Sternlicht and Werb, 2001). After the activation of 
MMPs from their latent zymogen form, they can be inhibited and regulated by 
compartmentalization or endogenous inhibitors. Compartmentalization prevents the 
indiscriminate release of MMPs and determines where and how they are released into 
the pericellular environment. This allows the enzymes to target their catalytic 
activities to specific substrates in the pericellular space without redundant proteolysis 
to surrounding tissues (O‘Connor and FitzGerald, 1994; Parks et al, 2004). 
Endogenous MMP inhibitors include tissue inhibitors of metalloproteinases (TIMPs) 
and α2-macroglobulin. Four TIMPs (TIMP-1, -2, -3, -4) inhibit MMP reversibly by 
binding to them in a 1:1 stoichiometric fashion, with each TIMP having varying 
affinity for different MMPs. The amino terminus of the TIMPs binds to the active site 
of the active MMP to render them inactive while the carboxy terminus prevents 
activation of the pro-MMP zymogen (Murphy and Willenbrock, 1995; Visse and 
Nagase, 2003). α2-macroglobulin, on the other hand, is present in the circulation and 
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binds irreversibly to MMPs, thus mediating their uptake by scavenger receptors 
(Chakraborti et al, 2003).  
 
The balance of MMPs and their endogenous inhibitors within the tissue regulates 
physiological and pathological tissue remodeling. Insufficient ECM degradation 
would interefere with normal physiological processes while excessive degradation 
would result in loss of cell-ECM attachment, leading to pathologic destruction of 
tissues (Snoek-van Beurden and Von den Hoff, 2005). MMPs have been linked to 
various pathological conditions including cancer, pulmonary diseases such as chronic 
obstructive pulmonary disease (COPD) and ARDS, arthritis, cardiovascular diseases 
and central nervous system (CNS) related injury such as multiple sclerosis and 
alzheimer‘s disease (Malemud, 2006). MMPs, in particular gelatinases MMP-2 and 
MMP-9, are responsible for basement membrane degradation that facilitates migration 
of tumor cells to blood vessels, aggravating metastasis during cancer. In addition, 
MMP-9 has been shown to release fibroblast growth factor and vascular endothelial 
growth factor which can aid tumor cell growth while MMP-7 promotes carcinoma cell 
survival (Stamenkovic 2003). MMPs play a significant role in CNS diseases because 
they disrupt the blood brain barrier and myelin through basement membrane 
degradation. The levels of MMPs in cerebrospinal fluid of multiple sclerosis patients 
are elevated, particularly MMP-9 (Yong et al, 2001).  MMPs in pulmonary pathology 
have also been extensively discussed. MMP-2, -8, -9 levels have been shown to be 
elevated in BALF of patients with ARDS, in which MMPs can degrade the alveolar 
basement membrane and cause increased permeability of the alveolar-capillary barrier 
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and impaired gas exchange (Fligiel et al, 2006). Chronically, ARDS can progress to 
fibrosis, which results due to aberrant wound healing and MMPs might contribute to 
abnormal tissue remodelling during the injury stage, due to ECM degradation, and the 
―attempted repair‖ stage. Lastly, MMP-1, -2, -8 and -9 have been found to be 
upregulated in BALF from COPD patients and is linked to the development of 
emphysema (Elkington and Friedland, 2006; O‘Connor and FitzGerald, 1994).  
 
2.10 Gelatinases  
Gelatinases include gelatinase A (MMP-2) and gelatinase B (MMP-9), which 
resemble each other with respect to primary structure and substrate specificity. With 
reference to figure 2.5, MMP-2 and MMP-9 degrade both type IV collagen and 
gelatin, which are major constituents of the basement membrane. Elastin and laminin 
have also been proven to be substrates of both gelatinases as well. In addition, MMP-
2 can also digest type I, II and III collagens while MMP-9 can digest type V collagen 
(Huhtala et al, 1991; McMillan et al, 1995; O‘Connor and FitzGerald, 1994). 
However, the sources of these two enzymes differ and MMP-2 is synthesized widely 
by a huge variety of cells, including alveolar epithelial cells, endothelial cells, 
fibroblasts, macrophages and dendritic cells while MMP-9 is mainly produced by 
inflammatory cells such as neutrophils, monocytes, macrophages and lymphocytes. 
Under certain conditions, MMP-9 can also be synthesized by endothelial and 
epithelial cells (Buisson et al, 1996; Corbel et al, 2000; Partridge et al, 1993; Segura-
Valdez et al, 2000). It it noteworthy that both gelatinases are differentially regulated 
at transcriptional and extracellular level, the former in which MMP-9 transcription is 
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strictly regulated by cytokines and growth factors while MMP-2 is only mildly 
responsive to these molecules; the latter in which TIMP-1 binds to pro-MMP9 while 
TIMP-2 binds to pro-MMP2. Furthermore, MMP-2 is the only member in the family 
which is constitutively expressed while MMP-9 expression is induced and their 
contributions to biological or pathological processes can be very different (Birkedal-
Hansen et al  ¸1993; Murphy and Crabbe, 1995).           
 
In the MMP family, gelatinases are considered one of the more integral subclass due 
to their ability of being able to degrade chief constituents of the basement membrane, 
including type IV collagen, laminin and gelatin. The basement membrane is a critical 
interface between epithelial cells and the rest of the body as it anchors the epithelium 
down to the connective tissue underneath, is a structural site for motility cue, acts as a 
mechanical barrier and is involved in angiogenesis, the development of new blood 
vessels (Vaccaro and Brody, 1981). The degradation of the basement membrane by 
gelatinases can thus lead to physiological as well as pathological processes. In normal 
physiological processes, gelatinases assist in ECM turnover and tissue remodelling 
such as cell migration, angiogenesis, wound healing and development (Opdenakker et 
al, 2001). To modulate inflammation, MMP-2 and MMP-9 degrade the basement 
membrane and allows leukocytes to enter and leave the blood to reach the site of 
injury or infection. Furthermore, they also cleave and activate pro-IL-1β, TNF and 
TGF-β, and in the case of MMP-9, aids in the recruitment of neutrophils by truncating 
the neutrophil chemoattractant interleukin-8 (IL-8) into a more potent form and also 
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generates Proline-Glycine-Proline (PGP), a tripeptide chemotactic for neutrophils 
(Gaggar et al, 2008; Koshikawa et al, 2000; Mook et al, 2004).   
 
Gelatinases are frequently implicated in many pathological conditions when 
uncontrolled enzymatic activity result due to the imbalance between the MMPs and 
their inhibitors. These include cancer, multiple sclerosis, cardiovascular diseases and 
a range of pulmonary injuries including ARDS, fibrosis and emphysema. The role of 
gelatinases in cancer has been extensively studied as they play a salient role in 
angiogenesis and cancer stage development. Angiogenesis is the formation of new 
blood vessels from existing vessels and MMP-2 and -9 contribute to this process by 
degrading the basement membrane, allowing the endothelial cells to detach and 
migrate into new tissues, as well as release ECM-bound proangiogenic factors such as 
vascular endothelial growth factor (VEGF)  and transforming growth factor β (TGF-
β). Furthermore, MMP-2 can initiate integrin signalling by itself, contributing to 
endothelial cell survival and proliferation. Gelatinases thus help provide a favourable 
environment for primary tumor growth and facilitates intravasation and extravasation 
of tumor cells in blood vessels, resulting in metastasis (Rundhaug, 2003). MMP-9 
appears to mediate central nervous tissue injury such as multiple sclerosis whereby 
patients show an elevated MMP-9 levels in their cerebrospinal fluid. MMP-2, on the 
other hand, has been linked to cardiovascular abnormalities in which its deficiency 
lead to pathological consequences (Malemud, 2006). In the lung, basement membrane 
is essential to maintain alveolar structure and integrity and its degradation will impair 
normal gaseous exchange between the alveoli and the pulmonary capillaries. In 
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COPD patients, elevated levels of MMP-9 correlates with emphysema development. 
In patients suffering from ALI and ARDS, degradation products of type IV collagen 
have been found in alveolar spaces and BALF samples contain highly elevated MMP-
2 and MMP-9 levels. It is suggested that the high concentration of MMP-9 present is 
highly correlated with neutrophil infiltration during ARDS and the extent of basement 
membrane digestion by this enzyme is a significant factor in determining disease 
outcome in ARDS, since the enzyme is able to disrupt the capillary-alveolar barrier by 
damaging both pulmonary endothelial and epithelial cells, resulting in edema (Corbel 
et al, 2000; O‘Connor and FitzGerald, 1994). Likewise, in human patients with 
pulmonary fibrosis, MMP-2 and MMP-9 have been shown to be upregulated and in a 
mouse model of pulmonary fibrosis, increase in gelatinase levels in the BALF was 
observed. Pulmonary fibrosis is a common end stage of many interstitial lung diseases 
and results due to aberrant wound healing, thus destroying the ECM scaffold of the 
alveoli in the process. MMP-2 and -9, together with other members, might contribute 
to abnormal tissue remodelling during the injury stage, due to ECM degradation, and 
the ―attempted repair‖ stage (Kim et al, 2009; O‘Connor and FitzGerald, 1994). 
 
Both MMP-2 and MMP-9 have been individually or collectively studied in various 
virus infections such as dengue virus (DV), sendai virus, respiratory syncytial virus 
(RSV) and human immunodeficiency virus (HIV). In the case of influenza virus, 
though the evidence for the link between influenza and MMPs, particularly the 
gelatinases, is exhibited, more in the recent years, the role of these MMPs in influenza 
virus infection is still not well elucidated. One of the first papers was Yeo et al, 1999, 
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where the authors investigated the effect of influenza A/Beijing/353/89 (H3N2) virus 
infection on the expression of MMP-2 and -9 in two epithelial cell lines: Vero cells 
and Madin-Darby Canine Kidney (MDCK) cells. In Vero cells, the expression of 
MMP-9 was stimulated, but not of MMP-2. However, in MDCK cells, only the 
MMP-2 production was increased. The modulation of gelatinases at the 
transcriptional level is thus, dependant on the epithelial cell line. MMP-9 has also 
been implicated in the pathogenesis of influenza-associated encephalopathy, a severe 
neurologic complication of influenza manifesting seizures and coma with high grade 
fever. By comparing the levels of MMP-9 and its inhibitor TIMP-1 in serum samples 
of influenza-infected human patients with or without neurologic complications, the 
authors observed a skewed balance of MMP-9 and TIMP-1, towards MMP-9 in the 
patients with neurologic conditions. This thus implies the MMP-9/TIMP-1 imbalance 
might contribute to damage of the blood brain barrier during virus infection, thus 
promoting encephalopathy (Ichiyama et al  ¸2007). In Gualano et al, 2008, the authors 
observed an increase in both MMP-2 and MMP-9 upon influenza A/Mem71 (H3N1) 
virus infection of BALB/c mice on day 3 post infection, and this increase was further 
elevated upon cigarette exposure. In the study of gene expression profiles in a murine 
model of influenza pneumonia, it was observed that the gene expression of MMP-2 
was increased and this trend persisted even till the day 14 post infection timepoint, 
where the virus was cleared and the C57BL/6 mice have already recovered from 
Influenza A/PR/8/34 virus infection (Dessing et al  ¸ 2009). Lastly, the most recent 
paper, Wang et al  ¸ 2010, identified a marked upregulation of both MMP-9 and 
proinflammatory tumor necrosis factor-α (TNF-α) in various organs upon Influenza 
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A/WSN/33 (H1N1) infection of C57BL/6 mice. MMP-9 activities were elevated in 
the damaged lung, brain and heart tissues and type IV collagen, a specific substrate of 
MMP-9, largely disappeared upon the upregulation of MMP-9 in the lung tissues. 
This correlated with the pathologic lesions of the mice lungs. The subsequent use of 
inhibitors decreased the expression of MMP-9 in the lung, brain and heart tissues and 
reduced pathological changes observed in the lung due to the viral infection. This 
study thus suggests a possible role MMP-9 has in pulmonary pathology and multiple 
organ failure during influenza virus infection.   
 
2.11 Exisiting therapies for Influenza  
Human influenza virus infection is usually uncomplicated, especially among young 
adults, and is self-limiting or can be treated symptomatically. However, in aged 
people and infants, treatment is necessary to prevent further complications of the 
infection and with the recent H1N1 ―Swine flu‖ outbreak, it is clear that therapeutic 
drugs are an important measure to control seasonal and pandemic influenza that may 
arise in the future. Although vaccination would be the best prophylactic defense, the 
current strategies for vaccine design and manufacturing are still not enough to cope 
with a sudden pandemic and therapeutic measures will be more realistic and effective 
in helping to cope with the infection.   
 
Four antiviral drugs are currently available commercially for the treatment of 
influenza A infection. Two of the antiviral drugs are neuraminidase inhibitors, namely 
oseltamivir (Tamiflu®) and zanamivir (Relenza®). The viral neuraminidase is 
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responsible for cleaving sialic acid residues on newly formed virions, facilitating their 
release and spread within the respiratory tract. Both oseltamivir and zanamivir have 
structures which closely mimic that of sialic acid and they act as competitive 
inhibitors of the neuraminidase, thus limiting virus spread and viral infectitivity. Of 
date, oseltamivir is currently the drug of choice for treatment of human H5N1 
influenza infection (Hsieh and Hsu, 2007; Hoffman et al, 2006). Amantadine and 
rimantadine, on the other hand, are M2 ion channel inhibitors and they are only active 
against influenza A virus, not influenza B, since the latter does not possess a M2 
protein (Hoffman et al, 2006). Both drugs inhibit replication of influenza A viruses by 
interfering with the virus uncoating within the cell. This is because, when the 
influenza virus enters the host cell by receptor-mediated endocytosis, acidification of 
the endocytotic vesicles is required for the dissociation of M1 protein from the 
ribonucleoprotein complexes thus the ribonucleoproteins are free to be transported to 
the nucleus to initiate viral RNA synthesis. Acidification of vesicles is through the M2 
channel, a passage for hydrogen ions, thus when rimantadine and amantadine blocks 
this channel, viral replication is disrupted (Hsieh and Hsu, 2007; Kamps and 
Hoffman, 2006).  Generally, neuraminidase inhibitors are considered better drugs than 
M2 ion channel inhibitors because they have fewer side effects and less drug 
resistance. Unfortunately, there is currently a widespread viral resistance against both 
drug classes, particularly the M2 inhibitors, owing to the ability of influenza viruses 
to mutate and reassert their genome segments. Thus, with the limited number of viral 
drug targets, it is imperative to develop new influenza therapies (Saladino et al, 2010). 
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Besides directly targeting the influenza virus, another strategy is to alleviate the host 
inflammatory responses to reduce the pulmonary pathology associated with infection. 
As reviewed in section 2.3, one of the fatal consequences of influenza virus infection 
is the host hyper immune response, in which intense inflammatory cytokine 
generation leads to excessive infiltration of inflammatory cells and eventually, 
massive epithelial and pulmonary damage. Intense inflammation will consequentially 
lead to ALI and ARDS. Various drugs have been proposed as immunomodulators for 
influenza strains, including the statins, macrolide antibiotics, pentoxifylline, 
resvertatrol and cinnamaldehyde and their use is to mitigate the hypercytokinaemia 
which results from severe influenza infection and prevent excessive cytokine 
production, thus reducing severity of the disease (Carter, 2007). A class of anti-
inflammatory drugs, corticosteroids, have also been used to treat influenza infected 
patients, which will maintain a balance of inflammation in infected patients and 
prevent respiratory distress. Postinfluenzal pneumonia was treated when patients were 
given cortisone or prednisolone, together with antibiotics, as these steroids not only 
corrected adrenal imbalance but also helped remove exudates in the alveolar spaces 
(Greaves et al, 1981; Plaza de los Reyes and Cruz-coke, 1957; Rotem, 1957).  
 
Since various MMP isoenzymes, in particular MMP-2 and MMP-9, are involved in 
pulmonary pathology including pneumonia, ALI or ARDS and emphysema, as 
reviewed in section 2.9, MMP inhibitors might be a potential class of therapeutic 
agents for reducing influenza-induced immunopathology in the lungs. Several 
mechanisms have been used to inhibit MMP activity and these include blocking RNA 
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synthesis, chelating zinc and binding to the MMP active site. To date, over 60 MMP 
inhibitors have been explored as clinical interventions in various diseases including 
cancer, arthritis and cardiovascular diseases. Of the list, at least ten are in clinical 
development and only Periostat®, also known as doxycycline hyclate, has been 
approved for use in periodontal disease (Corbitt et al, 2007; Fingleton, 2007). The list 
of MMP inhibitors currently in clinical testing is depicted in figure 2.7. However, 
pharmaceutical company interest in developing MMP inhibitors has diminished over 
the years, mainly due to the high incidence of dose-limiting side effects. This is 
attributed to the nonspecific inhibition of MMPs, as most of the currently developed 
MMP inhibitors are not only broad spectrum MMP inhibitors, but also block members 
of other families such as aminopeptidases, neprilysins and dipeptidylpeptides 
metalloproteinases. Thus, these MMP inhibitors might suppress key 
immunoregulatory functions and disrupt other critical pathways required for tissue 
homeostasis (Corbitt et al, 2007). One major hurdle of MMP inhibitor development 
would be to target specific MMPs to reduce side effects and this may be achieved by 
either generating inhibitors with a narrower spectrum of activity or by targeting 
pathways that regulate MMP secretion (Corbitt et al, 2007; Fingleton, 2007). MMP 
inhibitors have been shown to be an effective therapeutic agent in animal models 
whereby they can prevent pathological changes of emphysema and ARDS, conditions 
commonly observed in influenza virus-infected patients (Elkington and Friedland, 
2006). Carney et al, 2001 demonstrated the prophylactic use of a chemically modified 
tetracycline, COL-3, in a porcine model of ARDS and this combined MMP and 






















Doxycycline is a broad spectrum tetracycline antibiotic that has bacteriostatic effect 
on bacteria, through its ability to prevent access of acyl t-RNA to the acceptor site on 
the mRNA-30s ribosomal subunit complex, thus inhibiting the elongation process of 
bacterial protein synthesis (Smith and Cook, 2004). Besides its antibacterial effect, 
doxycycline has also been shown to be effective as antiprotozoal and antihelmintic 
agents (Batty et al, 2007; Lalloo et al, 2007; Smith and Cook, 2004; Taylor et al, 
2005). Other properties that have been recently ascribed to doxycycline include its 
anti-inflammatory activity, inhibition of MMP synthesis and activity, decrease in 
neutrophil chemotaxis, inhibition of protein kinase C activity, inhibition of nitric 
oxide synthase activity, inhibition of interleukin-1 synthesis and inhibition of 
activated B cell function (Sagar, 2010). The wide spectrum of activities that 
doxycycline possesses allows it to be used in various clinical conditions including 
periodontitis, rheumatoid arthritis, abdominal aortic aneurysm, multiple sclerosis, 
sarcoidosis, neutrophilic diseases and others (Sagar, 2010; Smith and Cook, 2004). 
 
As mentioned in section 2.10, doxycycline has been shown to be a non-specific MMP 
inhibitor and this inhibition occurs independent of its antimicrobial activity (Golub et 
al  ¸ 1990). It is the most potent MMP inhibitor in the tetracycline class and MMP 
inhibition in vivo is exhibited at subantimicrobial plasma levels (Cena et al, 2010). 
Doxycycline‘s role in MMP inhibition, in particular that of MMP-2 and MMP-9 has 
been extensively studied. A few mechanisms of MMP inhibition by doxycycline have 
been suggested: 1)Doxycycline downregulates MMP gene expression, 2)Doxycycline, 
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being a metal ion chelator, binds to the active zinc site in MMPs and secondarily to 
the inactive calcium ion site, thus causing conformational change and loss of 
enzymatic activity, 3)Doxycycline inhibits pro-MMP activation, as reported in Curci 
et al, 2000 in which activation of proMMP-2 was suppressed, 4)Doxycycline can 
scavenge the action of oxygen species that play a role in the activation of 
procollagenases and progelatinases in vitro (Chang et al, 2010; Kaito et al, 2003).  
 
Doxycycline have been shown to have protective actions via their MMP inhibitory 
actions in models of cardiovascular injury, abdominal aortic aneurysm, cancer and 
inflammation (Hidalgo and Eckhardt, 2001; Kaito et al, 2003; Liu et al  ¸2006). It has 
been observed to attenuate various pulmonary conditions as well. Lee et al, 2004 
reviewed the use of doxycycline in a murine model of toluene diisocyanate induced 
asthma and the drug reduced both airway inflammation and hyperresponsiveness. 
Doxycycline also attenuated acute lung injury in lipopolysaccharide (LPS)-instillation 
model. The administration of doxycycline during LPS injury reduced neutrophil 
migration in the lung and alveolar destruction, thus alleviating ALI symptoms. This 
correlated well with the decrease in gelatinase activity (Fujita et al, 2007). In another 
murine model of bleomycin-induced pulmonary fibrosis, administration of the drug 
showed a significant decrease in neutrophil numbers in the BALF and this was 
accompanied by a decrease in gelatinase expression and activity. Doxycycline 
attenuated pulmonary fibrosis, confirmed by lung histology and morphometry (Fujita 




CHAPTER 3: MATERIALS AND METHODS 
3.1  Use of BALB/c Mice and Animal Husbandry  
Female BALB/c mice of six to eight weeks old were used in this study. Animals were 
ordered and acquired from NUS Comparative Medicine Centre‘s breeding facility 
CARE and housed in micro-isolator cages in an Animal Bio-Safety Level Two 
containment facility at the Centre for Life Sciences Animal Vivarium. Animals were 
given food and water ad libitum. Animal protocol 035/07 was approved by the 
Institutional Animal Care and Use Committee, NUS. Mice were exposed to 12 hour 
day 12 hour night cycles.  
 
3.2  Intranasal Infection of Mice  
Mice were anesthesized intraperitoneally with 100μl of 7.5mg/ml ketamine and 
0.1mg/ml medetomidine mixture. After animals were rendered unconscious, mice 
were given 2 X 10
5
 plaque forming units (PFU) of a mouse-adapted passage 10 (P10) 
Influenza A/Aichi/2/68 (H3N2) virus in 40μl of 1X PBS intranasally. Previous work 
in our lab had established a mouse adaptation model through ten serial lung-to-lung 
passaging, of which this mouse-adapted influenza A/Aichi/2/68 (H3N2) virus is 
named Passage 10 (P10) (Teluguakula et al, 2009). The animals were revived with 
100μl of 1.0mg/ml of Anti-Sedan® atipamezole hydrochloride solution by 
intraperitoneal injection. Infected animals were kept in separate cages and were 
weighed daily to monitor for weight loss and to check for any premature mortality. 
Animals were euthanized if they exceeded 30% weight loss. The infection experiment 
involved 2 control groups and 2 infected groups: 1) Control group inoculated with 
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40µl of normal lung homogenate obtained from uninfected mice and kept for 3 days 
post-infection 2) Control group inoculated with 40µl of normal lung homogenate 
obtained from uninfected mice and kept for 6 days post-infection 3) Infected group 
inoculated with 40µl of lung homogenate from P10 virus-infected mice and kept for 3 
days post infection 4) Infected group inoculated with 40µl of lung homogenate from 
P10 virus-infected mice and kept for 6 days post-infection. The control groups contain 
6 mice each while the infected groups contained 10 mice each.  
 
3.3 Doxycycline Treatment  
Doxycycline hyclate (Sigma Aldrich, St Louis, USA) treatment of the mice was 
carried out daily, starting from 3 days prior to virus infection to day 6 post-infection. 
Day 6 post-infection was the endpoint of the experiment. Prophylactic administration 
of the drug was carried out instead of therapeutic administration because in previous 
studies involving influenza and bleomycin-induced pulmonary fibrosis, doxycycline 
administration after the onset of disease proved to be not as effective as compared to 
prior administration (Fujita et al, 2006; Ryan et al, 2009). The mice were 
administered 100μl of doxycycline hyclate, resuspended in water, by oral gavage. 
Mice were infected 3 days after the start of doxycycline treatment, with P10 Influenza 
A/Aichi/2/68 (H3N2) virus intranasally, as described in section 3.2. In this study, two 
doses of doxycycline, 20 mg/kg and 60 mg/kg, were used. The doxycycline 
experiment involved 3 control groups and 3 infected groups: 1) Control group 
inoculated with 40µl of normal lung homogenate and treated with water 2) Control 
group inoculated with 40µl of normal lung homogenate and treated with 20mg/kg of 
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doxycycline 3) Control group inoculated with 40µl of normal lung homogenate and 
treated with 60mg/kg of doxycycline 4) Infected group inoculated with 40µl of P10 
virus lung homogenate and treated with water, also known as the solvent control 
group 5) Infected group inoculated with 40µl of P10 virus lung homogenate and 
treated with 20 mg/kg of doxycycline 6) Infected group inoculated with 40µl of P10 
virus lung homogenate and treated with 60 mg/kg of doxycycline. The control groups 
treated with the two doses of doxycycline are important to evaluate any toxic effects 
the drug have on the mice. Control groups contain 4 mice each while infected groups 
contained 8 mice each.   
 
3.4  Broncho-Alveolar Lavage Fluid (BALF) Collection from Mice  
Mice marked out for each treatment group were euthanized on Days 3 and 6 post-
infection for the infection experiment. For the doxycycline experiment, mice were 
euthanized on Day 6 post-infection. To extract the BALF from the mice, the bronchus 
of the left lung of each mouse was tied and a small incision was made in the upper 
trachea after it was exposed. A 23G needle fitted with a thin rubber tubing (Clay 
Adams, USA) was then inserted into the trachea before the tip of the needle reached 
the bifurcation point of the bronchi. The right lung was then washed twice with 0.4ml 
of cold sterile 1X PBS each time. 90% of the instilled PBS was recovered and the 
BALF was stored on ice to preserve the cells. BALF samples were then spun at 
1100xg for ten minutes, 4°C. The BALF cell pellets were resuspended in 1X PBS and 
used for total and differential cell count while the supernatant was aliquoted for (a) 
Gelatinase zymography (b) Western Blot and (c) BALF protein estimation.  
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3.5 BALF Cell Counts 
3.5.1 Total BALF Cell Count using trypan blue exclusion 
BALF cell pellets, discussed in section 3.4, were resuspended in varying volumes of 
1X PBS. Cells were resuspended in varying volumes of 100μl to 800μl to achieve 
sufficient dilution for subsequent steps. 10μl of the resuspended cell solution is mixed 
with 10μl of trypan blue, followed by the addition of the mixture between the 
coverslip and the Neubauer hemocytometer. Cells were counted from four large 
squares under the microscope. The average count from the four squares was obtained 
and the total number of BALF cells was calculated as follows: 
Average number of cells x 10
4
 x dilution factor x volume of cells 
 
3.5.2 Differential BALF cell count using Giemsa staining 
A microscope glass slide was loaded onto a stainless steel slide clip (Shandon 
Cytoclip®, Thermo Scientific, USA) and a paper filter card was inserted and 
sandwiched in between the glass slide and a plastic Cytofunnel® (Thermo Scientific, 
USA) used for loading of sample. 50μl of 1X PBS was loaded into the funnel and 
placed in a Shandon Cytospin III® cytocentrifuge (Thermo Scientific, USA). The 
PBS-loaded funnels were centrifuged at 600rpm for 2 minutes for washing. 40μl of 
the cell suspension was then loaded into the funnels after this initial 2 minute round of 
centrifugation. The samples were centrifuged at 600rpm for 6 minutes, to allow the 
cells to adhere to the microscope slides for later enumeration and differential cell 
counts of BALF cells. Cells adhered to the slides were then subjected to modified 
Giemsa staining and 200 cells per sample were counted at a magnification of 400X.   
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3.6 Lowry Protein estimation Assay of BALF and Lung homogenate 
Protein estimation by means of the LowryHS method was done for BALF 
supernatant, as previously discussed in section 3.4. The assay was done with the 
BioRad© RC DC Protein Assay. 2μl of the BALF samples was aliquoted into a 1.5ml 
microfuge tube and 28μl of 1X PBS was added to achieve a total volume of 30μl. 
20μl of Reagent S was added to 1ml of Reagent A from the RC DC protein assay kit 
(BioRad Laboratories) and 125μl of this mixture was then added to the 30μl diluted 
BALF sample. 1ml of Reagent B was then added and the mixture was vortexed to 
ensure thorough mixing of sample. This reagent and sample mixture was then left to 
stand for 15mins. This mixture was then analyzed with a Beckman Coulter ® Du 
640B spectrophotometer at 750nm for colorimetric analysis of protein concentration. 
The protein concentrations obtained in this assay would help to evaluate protein 
leakage into the air spaces of the lung. This same protein estimation assay was 
performed on lung homogenate samples which would be used for MPO activity assay 
and plaque assay, described in sections 3.12 and 3.21 respectively (Lowry, 
Rosebrough et al. 1951). The values were then used for normalization of MPO 
activity and virus titre to protein concentrations of the lung homogenates. 
 
3.7 Gelatinase zymography  
BALF supernatant obtained from mice, as discussed in section 3.4, was subjected to 
gelatinase zymography to determine presence and activity of MMP-2 and MMP-9. 
20μl of BALF supernatant mixed-sample buffer (250Mm Tris-HCL, pH 6.8, 40% v/v 
glycerol, 8% v/v SDS and 0.01% bromophenol blue) was subjected to electrophoresis 
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in a 10% SDS-polyacrylamide gel (BioRad Laboratories) with 1mg/ml gelatin (Sigma 
Aldrich, St Louis, MO). The run was carried out at 80V for around 2 hours. The gels 
were then rinsed with 2.5% Triton-X for 30 mins with gentle agitation at room 
temperature. This was followed by rinsing of the gel with H2O for 3 times, 5 mins 
each, to remove the Triton-X. The gels were subsequently incubated in developing 
buffer (50mM Tris-HCL, pH 7.7, 200mM NaCl, 5mM CaCl2 and 0.2% v/v Brij-35) 
for 30 mins at room temperature with gentle agitation. Decant the developing buffer 
and replace with fresh developing buffer, of which the gels were incubated at 37°c for 
16h. After this overnight incubation, the gels were stained with 0.5% Coomassie 
brilliant blue R-250 (Sigma Aldrich) for 1-2 hours and destained with a solution 
containing 10% v/v methanol, 5% v/v acetic acid in H2O. Gelatinase activity was 
determined with the presence of clear bands in a blue stained background. The same 
procedure was carried out for supernatant obtained from mammalian LA-4 cells (refer 
to section 3.20.3) to determine MMP-2 and MMP-9 protein activity.  
 
3.8 Western blot analysis  
BALF supernatant obtained from mice, as discussed in section 3.4, was subjected to 
western blot analysis to study protein expressions of MMP-2, MMP-9, T1-α and 
Thrombomodulin. BALF samples were solubilized in SDS sample buffer (62.5 mM 
Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 2% SDS, 10% glycerol and 0.01% 
bromophenol blue) and subjected to electrophoresis in a 9% and 11% SDS-
polyacrylamide gel, for MMP-2 and the other proteins respectively. The run was done 
at 100V for 90mins. The samples were then transferred onto a PVDF membrane 
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(Amersham Biosciences, GE Healthcare) at 60V for 90mins and to check the 
efficiency of protein transfer, each membrane was stained with Ponceau stain, and 
blocked for 2 h with 5% milk in 100 mM Tris-buffered saline containing 0.1% Tween 
20 (TBS-T). Each membrane was incubated at 4°C overnight with appropriate 
dilutions of primary antibodies. Rabbit anti-MMP-2 (Abcam) (1:2000), Rabbit anti-
MMP-9 (Santa Cruz) (1:200), Mouse anti-T1-α (Developmental Studies Hybridoma 
Bank, University of Iowa, Iowa City, IA) (1:500) and Mouse anti-Thrombomodulin 
(Santa Cruz) (1:200) antibodies were used. After the overnight incubation, each 
membrane was washed thrice, 5 mins each, in TBS-T, and incubated with HRP-
conjugated anti-mouse or anti-rabbit IgG (Santa Cruz Biotechnology) (1:5000) for 1 
h. After washing thrice for 5 min each time, each blot was developed with ECL 
reagents (Amersham Biosciences) and exposed to X-ray film to visualize the protein 
bands. Densitometric analyses were performed using a Bio-Rad densitometer for all 
proteins. The same procedure was carried out for supernatant obtained from 
mammalian LA-4 cells, as discussed in section 3.20.3. Western blot analysis was done 
to study protein expressions of MMP-2 and MMP-9 in the mammalian cell samples.  
 
3.9 Extraction and Preparation of Lungs for Histopathology  
The lungs were harvested from each euthanized animal. The lung which was not 
washed with PBS for the lavage fluid collection was sectioned into 4 transverse 
sections. The top and bottom sections of the left lung were put into 0.6ml microfuge 
tubes and immediately preserved in liquid nitrogen and later on preserved in -80°c. 
These tissue sections were used for lung homogenization, discussed in section 3.11. 
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The middle two sections were carefully placed in 4% v/v of formalin in 1X PBS 
(Merck). These two sections were subsequently used for histopathology. Formalin-
fixed lung tissues were delivered to the Department of Pathology, National University 
Hospital (NUH) for microtome sectioning and Hematoxylin & Eosin (H&E) staining.  
 
Stained sections were observed under a light microscope at 100X magnification and 
scored by a single trained pathologist from NUH, Dr Seet Ju Ee, who was blinded to 
the identity of the samples. Because of the hugely varying amount of lung tissue 
present on any one slide, an overall score was assigned per case, rather than counting 
specific numbers of fields. This was thought to be reasonable as influenza usually 
diffusely affects the lungs. If a particular slide showed uneven involvement, the worst 
area was scored and a comment was made. A scoring system based on the extent of 
inflammation was devised as follows - 0: Normal; 1: Bronchiolitis only, not affecting 
surrounding alveoli; 2: Bronchiolitis and peribronchiolar alveolitis; 3: Bronchiolitis 
and alveolitis affecting airspaces away from bronchioles, patchy, <50%; 4: 
Bronchiolitis and alveolitis affecting airspaces away from bronchioles, patchy, >50%; 
5: Bronchiolitis and alveolitis affecting airspaces away from bronchioles, diffuse,  
>50%. 
 
3.10  Immunohistochemistry 
Lung sections were deparaffinized in xylene, twice for 5 mins, and subjected to 100% 
and 90% ethanol rehydration of 3 mins each. The slides were then washed with 1X 
PBS followed by permeabilization with 0.1% Triton X-100 in PBS for 30 mins. Lung 
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sections were subsequently blocked with 4% fetal bovine serum (FBS) in PBS for 60 
mins and incubated at room temperature for 6h with appropriate dilutions of primary 
antibodies. These include rabbit anti-Collagen IV (1:200) and rabbit anti-influenza 
virus (1:300). After washing thrice with PBS for 5 min, the slides were incubated with 
1:200 dilutions of secondary antibodies conjugated to Alexa 555 (Molecular Probes, 
Eugene, OR) at room temperature for 20 min. The slides were washed thrice with 
PBS, mounted with DAPI, and examined using an Eclipse E600 fluorescence 
microscope (Nikon, Tokyo, Japan).  
 
3.11 Homogenization of Lungs 
The sections of lungs unwashed by PBS during lavage fluid collection were removed 
from -80°c and placed into liquid nitrogen. The individual tissues from each animal 
was then placed in a sterile mortar and ground in liquid nitrogen with a sterile pestle 
into a fine powder. 300μl of sterile 1X PBS was then added into the mortar to dissolve 
and resuspend the ground tissue. This suspension was aliquoted into a 1.5ml 
microfuge tube and spun at 5000rpm for five minutes. The supernatant was then 
extracted and aliquoted into a centrifugal microfuge filter unit of 0.45μm porosity 
(Millipore, USA). This was spun at 13,000rpm for ten minutes to ensure that all the 
lung homogenate was collected in the flow through and that the filtered lung 
homogenate was free of bacterial contamination. The supernatant was then directly 
used for (a) plaque assay using MDCK cells, as described in section 3.21 and (b) 
myeloperoxidase (MPO) assay, as described in section 3.12. For tissues designated for 
RNA extraction, 300μl of lysis buffer, Buffer RLT (Buffer RLT had been 
 55 
 
supplemented with β-mercaptoethanol (Merck) by adding 10 µl of β-mercaptoethanol 
per ml of Buffer RLT), was added to resuspend the ground tissue instead of PBS. 
RNA extraction is described in section 3.14. 
 
3.12 Myeloperoxidase (MPO) Enzyme Activity Assay  
MPO activity in the lung homogenate was assayed as described in Narasaraju et al, 
2003. 20μl lung homogenate was mixed with 980μl of MPO assay solution. The latter 
was prepared fresh before use by mixing 107.6ml of H2O, 12ml of 0.1M sodium 
phosphate buffer (pH 7.0), 0.192ml of guaiacol, and 0.4ml of 0.1M H2O2. The 
generation of tetraguaiacol was measured spectrophotometrically at 470nm 
wavelength, and the change in optical density (OD) per minute was calculated from 
the initial rate. The MPO activity was then calculated using the formula (units/ml = 
OD/min × 45.1), and expressed as units per mg protein. One unit of the enzyme is 
defined as the amount that consumes 1μmol of H2O2 per min. 
 
3.13 Streaking of blood agar plate with lung homogenate 
Lung homogenate was streaked onto a blood agar plate to look for presence of 
secondary bacterial infection due to influenza virus infection of the host. Blood agar 
plate was used because it is an enrichment medium, thus allowing common and even 
fastidious microbes to grow on it. A sterile loop was used in this procedure. Remove a 
loopful of lung homogenate from section 3.11 and streak the lung homogenate over a 
small area at the top of the blood agar surface. Streak this suspension from the top to 
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the bottom in a zig zag manner and incubate the plates at 37°c for 48 hours. Observe 
for colony formation. 
 
3.14  Total RNA Purification from Animal Tissues and Mammalian Cells 
Total RNA extraction was performed using the RNeasy® mini kit (Qiagen, Hilden, 
Germany). One volume of 70% ethanol was added to the lung sample containing 
Buffer RLT lysis buffer, as previously described in section 3.11, and the 600µl 
mixture was transferred into a spin column, spun at 11,000rpm for 1 min. The flow-
through was discarded and 350µl wash buffer, Buffer RW1, was added into the spin 
column before spinning at 11,000rpm for 1 min. Discard the eluate. The columns 
were then treated with DNAse for 15 min at room temperature, after which 350µl 
buffer RW1 was added into the column. After spinning at 11,000rpm for 1 min, the 
flow-through was discarded and subsequently, washing was performed twice using 
500μL Buffer RPE. The RNeasy spin column was centrifuged at 12,000rpm for 1 min 
to ensure thorough drying and removal of any residue buffer. The RNA was then 
eluted in 40 μL of RNase-free water and stored at -80°C for later use. Total RNA 
extraction was also performed on LA-4 mammalian cells, discussed in section 3.20, 
using the same procedure.  
 
3.15  Quantitation and determination of purity and integrity of total RNA 
The isolated total RNA was quantitated by UV spectrophotometry at 260 nm using a 
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE). 
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urity was ensured by an OD260/OD280 ratio of  1.8-2.1. A qualitative analysis of 
RNA was also performed by loading 200ng of RNA in a 1% Seakem® LE agarose 
gel (Cambrex, ME, USA) and the bands separated by electrophoresis. RNA samples, 
which produced two clear bands of ribosomal RNA when visualized under a Kodak 
DC290 digital camera, were again verified to be of sufficiently good quality and 
suitable for subsequent analytical steps.  
 
3.16 Reverse transcription 
500ng of RNA was used for reverse transcription into cDNA. This was done by using 
previously obtained values of RNA concentration and extracting appropriate volumes 
for the reverse transcription reaction. This volume of RNA was then topped up with 
additional RNase-free water to a volume of 26μl. 8μl of 5X RT Buffer (Promega, 
Madison, WI), 2μl of Random Hexamer (Promega, Madison, WI), 2μl of 10mM 
dNTP (Promega, Madison, WI) and 1μl of RNasin® RNase inhibitor were prepared 
for each sample for reverse transcription. The reaction mixture of 39μl now was 
subjected to a linearization step to denature any loops or folds formed between the 
RNA molecules. This was done by placing samples in a thermal cycler (BioRad 
laboratories, USA) at 70°c for 5mins. After this step was complete, 1μl of MMLV 
Reverse Transcriptase (Promega, Madison, WI) was added to the reaction mixture. 
The tubes containing the 40μl RNA samples were then allowed to complete the 
reverse transcription reaction in the thermal cycler, at 37°c for 60mins and held at 4°c. 
The generated cDNA samples were then analyzed by using the Nanodrop® ND-1000 
Spectrophotometer (Nanodrop Techonologies, Wilmington, USA) to check for the 
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quality of the cDNA and the reverse transcription reaction. cDNA samples of OD 
ratios of 260/280 of 1.6-1.8 were considered pure.  
 
3.17 Classical PCR for viral gene detection 
Polymerase chain reaction (PCR) amplification was performed using the cDNA 
template obtained from reverse transcription. To detect for presence of virus, a pair of 
primers was designed to amplify the influenza virus PA2 gene. The pair of primers 
used for the viral PA2 gene is shown in table 3.1. The 25ul PCR reaction mix 
contained 0.5µl of 10mM dNTP, 0.25µl of 100µM forward and reverse primer each 
(1
st
 Base), 2.5µl of 10X PCR buffer (New England Biolabs, Ipswich, MA), 0.1µl of 
Taq DNA Polymerase (New England Biolabs, Ipswich, MA), 1µl of cDNA and 
topped up with nuclease-free water. Thermal cycling conditions were 94°c for 5 min, 
followed by 35 cycles of 94°c for 1 min, 56°c for 1 min and 72°c for 1 min. The final 
extension time was 72°c for 10 min. The samples were then held at 4°c and 
electrophoretically separated in a 1% Seakem® LE agarose gel (Cambrex, ME, USA) 
and visualized using a Kodak DC290 digital camera. 
 
3.18 SYBR Green Real time analysis of genes  
Real-time quantitative PCR with a SYBR Green-based method in a LightCycler 
system (Roche, Basel, Switzerland) was done on the reverse transcribed RNA 
obtained from the mice lungs. Primers were designed for genes coding for MMP2, 
MMP9 and β-actin by using Gene Runner® software to mimimize the occurrence of 
primer dimers, internal, and hairpin loops which would confound and interfere with 
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the downstream PCR reactions (1st Base Pte Ltd, Singapore). The sequences of the 
primers used for amplification are shown in table 3.1. 14μl of Light Cycler® Fast 
Start Enzyme was added to each vial of Light Cycler® reaction mix to produce the 
SYBR Green fluorescent marker (Roche Diagnostics, Singapore). 5μl of nuclease-free 
water, 0.5μl of forward primer, 0.5μl of reverse primer, 2μl of cDNA and 2μl of 
SYBR Green were used for each analysis of an individual sample for every gene. 
Technical replicates of every gene analyzed were also carried out to ensure reliability 
and accuracy of the threshold values obtained. The reaction mix was pipetted into a 
20μl glass capillary (Roche Diagnostics) and the capillaries were transferred to and 
inserted into the 32 chamber Light Cycler® 2.0 instrument (Roche Diagnostics). A 
negative control was used for every run, which used nuclease-free water in place of 
the cDNA. Reactions were subjected to an initial denaturation of 95°c for 10 min, 
followed by 40 cycles each of 95°c for 10 s, 55-60°c for 5 s and 72°c for 30 s, before 
being subjected to melting curve analysis. Ct values as well as melting curves were 
obtained by the Light Cycler® software after every run. Corresponding Ct values 
were accepted only if the run produced sample melting curves showing a single 
consistent peak, indicating a uniform product amplified by the PCR. The Ct values 
were noted down for calculation of gene expression in terms of fold change relative to 
the ―housekeeping‖ gene, β-actin (Sim et al, 1999; Sim et al, 2002). The normalized 
Ct values of each gene were subjected to Student‘s t-test with two-tailed distribution 













     
*Housekeeping gene used as endogenous normalizing control in real-time PCR. 
 
Table 3.1. Sequences of primers for the amplification of genes by classical or real-time PCR 
 
 























3.19 Cell culture  
MDCK cells (ATCC Number CCL-34) were cultured in a growth medium, consisting 
of minimum essential medium (Eagle) (Sigma Aldrich, St Louis, MO) supplemented 
with 2 mM L-glutamine and Earle‘s BSS adjusted to contain 1.5 g/L sodium 
bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, 10% fetal 
bovine serum (FBS), at 37°c under 5% CO2 in a humidified incubator. LA-4 cells 
(ATCC Number CCL-196) were cultured in F-12 medium (Gibco Invitrogen, 
Carlsbad, CA), supplemented with 20% FBS, at the same conditions as MDCK cells. 
For passaging, medium was first removed and the cells were rinsed with 1X PBS 
twice. The cells were then trypsinized with 2 ml of 1X trypsin-EDTA solution 
(Invitrogen, Carlsbad, CA) for a 25 cm
2 
culture flask. Once the cells showed signs of 
detachment under a microscope, 6 ml of fresh medium was flushed into the flask to 
detach the cells completely. 8 ml of fresh medium was added to 2 ml of cell 
suspension in a new 25 cm
2
 culture flask and was mixed well before incubation. 
Incubate cells until confluent growth is observed under the microscope. 
 
3.20  Virus infection of LA-4 cells  
3.20.1 Seeding of cells in 24-well plate or 6-well plate 
LA-4 cells from 75cm
2
 culture flasks were trypsinized and enumerated by trypan blue 
exclusion method, as described in section 3.5.1. 0.6 X 10
5
 cells and 0.5 X 10
6
 cells 
were seeded in each well of a 24-well plate and 6-well plate respectively, and grown 
in 20% FBS F-12 medium. Cells seeded in 24-well plate were used for RNA work 
while those seeded in 6-well plate were used for protein work such as (a) gelatinase 
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zymography and (b) western blot. The cells were incubated for 24h at 37°c under 5% 
CO2 in a humidified incubator to allow the cells to attach to the wells and to obtain a 
confluent layer the next day.  
 
3.20.2  Virus infection of LA-4 cells 
2 mutiplicity of infection (MOI) of mouse adapted P10 Influenza A/Aichi/2/68 virus 
were used to infect LA-4 cells in both 24-well and 6-well plates. F-12 growth medium 
was completely removed from each well and the cells were rinsed twice with 1X PBS 
to remove any traces of trypsin. For the 24-well plate, the cells in the infected wells 
were inoculated with 120μl of virus in serum free medium containing 0.5μg/ml 
TPCK-trypsin while for the control wells, 120μl of serum free medium containing 
0.5μg/ml TPCK-trypsin was added to each well, with the absence of virus. For the 6-
well plates, 500μl of inoculum was used instead. The plates were then incubated at 
37°c with occasional rocking for 2h. After the 2h incubation, the virus and TPCK 
medium were removed and replaced with 250μl and 1ml of serum-free medium in 24-
well and 6-well plates respectively. The plates were kept in a humidified incubator at 
37°c under 5% CO2 for various timepoints: 0h, 12h, 24h and 48h. 
 
3.20.3  Harvesting of cells and supernatant for subsequent experiments 
At timepoints 0h, 12h, 24h and 48h, cells and supernatant were harvested from the 
wells in the 24-well and 6-well plates for subsequent experiments. For the 24-well 
plate, 250μl of supernatant was extracted and stored at -80°c for virus titre 
determination by plaque assay, discussed in section 3.21. 300μl of lysis buffer, Buffer 
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RLT, was added to the cells left in the well and a cell scraper was used to remove and 
transfer the cell suspension into a 1.5ml microfuge tube. RNA extraction was 
subsequently carried out on these mammalian cell samples, as discussed in 3.14. The 
RNA samples extracted was subjected to reverse transcription and classical PCR, 
using the protocols described in sections 3.16 and 3.17, to detect viral PCR gene. 
Real-time PCR, as described in section 3.18, was also done on these mammalian cell 
samples to study gene expressions of MMP-2 and MMP-9. For the 6-well plate, 500μl 
of supernatant was extracted each for gelatinase zymography and western blot 
analysis. These samples were stored at -80°c and gelatinase zymography and western 
blot analysis were discussed respectively in sections 3.7 and 3.8. 
 
3.21  Plaque assay for virus titre 
3.21.1 Seeding of cells in 24-well plate 
MDCK cells from 75cm
2
 culture flasks were trypsinized and enumerated by trypan 
blue exclusion method, as described in section 3.5.1. 1 X 10
5
 cells were seeded in 
each well of a 24 well plate in 10% FBS EMEM medium. The cells were incubated 
for 24h at 37°C under 5% CO2 in a humidified incubator to allow the cells to attach to 
the wells and to obtain a confluent layer on the following day. 
 
3.21.2  Infection of MDCK cells with virus 
The cell supernatant from section 3.20 or lung homogenate from section 3.11 were 




 in a 24-well plate with serum free 
medium containing 1μg/ml TPCK-trypsin. The growth medium was completely 
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removed from each well and the cells were rinsed twice with 1X PBS to remove any 





  in duplicate for each plate. The plate was incubated at 37°C with 
occasional rocking for 1h. 
 
3.21.3 Preparation and addition of Avicel overlay 
After the 1h incubation period, the inoculum was removed and overlaid with 1ml of 
1.2% Avicel before incubating at 35°C for 2 days. Stock suspensions of Avicel was 
prepared by resuspending 2.4g of Avicel RC-591 powder (FMC BioPolymer, 
Philadelphia, USA) in 100ml nanopure water on a standard magnetic stirrer for 1h. 
Avicel stocks were sterilized by autoclaving for 20min at 121°C and stored at room 
temperature. The overlays were prepared by mixing stock solutions of Avicel with 
equal volumes of double-strength MEM.  
 
3.21.4 Fixation and staining to visualise plaques 
After the incubation period, the overlay was removed and cells were fixed with 20% 
formaldehyde solution for 1h. Following fixation, the solution was removed and the 
cells were washed twice with 1X PBS. The cells were then stained with 0.5ml of 1% 
crystal violet for another 30min, after which the stain was washed off with water. The 
plates were then air-dried at room temperature and the plaques were counted. The 
plaque forming units (PFU) was calculated as follows: 




3.22  Statistical Analysis  
Results obtained were expressed as a mean value ± standard deviation. The Student‘s 
t-test was used to perform statistical analysis and comparison of samples. Values of 






















3.23 Summary of methodology 
















*Control wells were infected with serum free medium containing 0.5μg/ml TPCK-trypsin  
 
 
Figure 3.1. Schematic diagram to summarise in vitro experiments 
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3.23.2  Summary of methodology (In Vivo) 
















*Control mice were inoculated with normal lung homogenate obtained from uninfected mice  
 
Figure 3.2. Schematic diagram to summarise in vivo mice infection experiments 
 
 
6-8 Weeks Old BALB/c mice  
Intranasal administration of 40μl (2 x 105 PFU) of 
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*    Control mice were treated with water instead of Doxycycline Hyclate 
**  Control mice were inoculated with normal lung homogenate obtained from uninfected    
       mice 
 




Oral Gavage of 100μl (20mg/kg or 60mg/kg) of 
Doxycycline Hyclate*  
Intranasal administration of 40μl (2 x 105 PFU) of 




































CHAPTER 4: MODULATION OF GELATINASES BY INFLUENZA A VIRUS  
 
4.1  RESULTS 
4.1.1  Microarray analysis of MMP gene expression  
The transcriptomic analysis of severe murine pneumonitis induced by mouse-adapted 
influenza A/Aichi/2/68 (H3N2) P10 virus was previously described by our lab 
(Unpublished data). Mice in the infection group were inoculated intranasally with 1.0 
X 10
5
 TCID50 of mouse-adapted Influenza A/Aichi/2/68 P10 virus while mice in the 
control group were inoculated with normal uninfected lung homogenate. At the 96h 
post-infection timepoint, infected mice displayed severe pneumonitis and microarray 
analysis revealed an upregulation in gene expression of various members of the MMP 
family, including MMP-3, MMP-8, MMP-9, MMP-13 and MMP-14, relative to 
control mice. With reference to figure 4.1A, the gene expressions of MMP-3, MMP-8, 
MMP-9, MMP-13 and MMP-14 increased by 9.5 fold, 7.3 fold, 11.56 fold, 2.495 fold 
and 3.77 fold respectively. The upregulation of these genes were further validated 
with real-time quantitative PCR. The respective fold changes were 14.8 fold, 233.9 
fold, 14.2 fold, 3.2 fold and 6.7 fold when compared to control mice (Figure 4.1B). 
The real time data for the 3.2 fold change of MMP-13 gene was not statistically 
significant. The elevated expression trends by both methods are similar but real-time 






4.1.2 Average weight of mice   
The weights of the mice sacrificed on both days 3 and 6 post-infection were 
monitored daily and measured every 24h before they were euthanized. The control 
groups of mice which were culled at day 3 and day 6 post-infection showed no weight 
loss and had average weights of (102 ± 2.44)% and (103 ± 2.97)% respectively, when 
expressed as a percentage relative to their initial weights on day 0 (Figure 4.2). Mice 
inoculated with Influenza A/Aichi/2/68 (H3N2) P10 virus and euthanized on day 3 
post-infection on average weighed only (87.1 ± 1.96)% of their average initial 
weights. For the infected group culled on day 6 post-infection, average weights of 
mice exhibited a more marked decrease to (77.8 ± 2.28)% of their initial weights at 
this timepoint (Figure 4.2). The two groups of mice infected with influenza virus not 
only exhibited significant weight loss, but the virulence of the virus was also directly 
evidenced by other clinical symptoms such as general lethargy and ruffled fur. These 













Figure 4.1. Fold change of genes in infected mice lung tissues as compared to 
control mice lung tissues at 96h post-infection timepoint. (A) Microarray data (B) 
Real-time quantitative PCR data. *Statistically significant p-value <0.05 









































4.1.3 Virus titres of mice lung homogenates determined by plaque assay 
Figure 4.3 shows the virus titres of lung samples obtained from control mice, infected 
mice culled day 3 post-infection and infected mice culled day 6 post-infection, as 
determined by plaque assay using MDCK cells. Control mice lung homogenates 
obtained from both day 3 and 6 post-infection showed no plaques at all, thus 
indicating absence of virus. Virus titres of mice lung homogenates obtained on day 3 
post-infection increased significantly to 3.4 X 10
4
 pfu/mg protein while on day 6 post-
infection, virus titres were reduced to 4.2  X 10
3 
pfu/mg protein. The increase of virus 
titres in both infected groups were statistically significant as compared to the control 
groups of mice.  
  
4.1.4 Immunohistochemical detection for influenza virus antigen in lung tissues  
Immunohistochemistry using polyclonal anti-influenza virus was done in lung tissue 
sections to indicate presence of virus upon infection. With reference to figure 4.4, at 
both 400X and 1000X magnifications, lung tissues from control mice represented by 
A and B respectively, showed no staining for virus. Lung tissues from infected mice, 
taken on day 3, showed strong positive staining for virus, mainly in the bronchiolar 
epithelium (arrow) and also in alveolar regions (arrowheads). These were represented 
by images C and D in figure 4.4. Lung tissues from infected mice, taken on day 6, 
stained positive for virus as well but staining was less diffused compared to day 3 and 
was more restricted to the bronchiolar epithelium (arrow), represented by images E 












Figure 4.2. Average weights of mice on days 0 to 6, expressed as a percentage of 
the average weight of the individual groups on day 0. Error bars represent SEM of 




Figure 4.3. Virus titres of mice lung homogenates, expressed in pfu/mg protein. 
Values were obtained by performing plaque assay where filtered lung homogenates 
were used to infect MDCK cells. Virus titres were then normalised to protein 
concentrations of the lung homogenates, to account for the varying sizes of lung 
tissues used for homogenization. Error bars represent SEM of the animals in each 
group (Control: n=6, Infected: n=10) **Statistically significant p-value <0.01 as 





























































Control (Culled Day 3)
Control (Culled Day 6)
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Figure 4.4. Immunohistochemical detection of influenza virus antigen in lung 
sections counterstained with DAPI nuclear dye. Representative images of each 
group were taken at 400X magnification (A, C, E) and 1000X magnification (B, D, 
F). A and B are images of lung tissues from control mice while C and D are lung 
tissues from infected mice at the Day 3 timepoint. Lung tissues from infected mice, 
taken on day 3, showed strong positive staining for virus, mainly in the bronchiolar 
epithelium (arrow) and also in alveolar regions (arrowheads). E and F are 
representative images of lung tissues from infected mice at the Day 6 timepoint. Lung 
tissues from infected mice, taken on day 6, stained positive for virus as well but 
staining was less diffused compared to day 3 and was more restricted to the 







4.1.5 Histopathology of lung tissues of mice 
Figures 4.5A to 4.5D represent lung tissues obtained from control groups of mice 
culled at timepoints day 3 and day 6 post-infection. These images show bronchioles of 
normal thickness, made up of columnar epithelial cells, accompanied by normal, well-
structured alveoli. All the airspaces were clear of infiltrates. Upon infection with 
mouse-adapted A/Aichi/2/68 (H3N2) P10 virus, pathologic lesions appear in lung 
tissue sections of the mice. Figures 4.5E and 4.5F represent lung tissues obtained from 
infected groups of mice culled at day 3. As seen from figure 4.5E, there was slight 
hyperplasia of bronchioles on day 3 post-infection, along with infiltration of 
inflammatory cells into the bronchioles (As indicated by the arrows) and less 
infiltration into alveoli surrounding the bronchiolar regions (As indicated by 
arrowheads). Figure 4.5F provides a magnified view of the infiltration in the 
bronchioles. Most of the infiltrates were mononuclear macrophages and fewer 
neutrophils were present. Figures 4.5G and 4.5H represent lung tissues obtained from 
infected groups of mice culled on day 6 post-infection. It is apparent from figure 4.5G 
that there was severe bronchiolitis (As indicated by the arrows) with massive 
inflammatory infiltrations in the alveolar region (As indicated by arrowheads). 
Bronchioles showed more prononunced hyperplasia, seen by the thickened columnar 
epithelial cells, as compared to that of day 3 post-infection. Loss of bronchiolar 
epithelium and diffused alveolar damage were detected in the lungs of these infected 
mice. A magnified view of the bronchioles was represented by figure 4.5H and 
extensive infiltration of both macrophages and neutrophils were observed in the air 
 76 
 
spaces of the bronchioles, accompanied by leakage of proteins, as indicated by the 
asterisk.  
 
Figure 4.6 shows histopathological scores of the Hematoxylin and Eosin (H & E) 
stained lung tissue sections, scored by a trained histopathologist, Dr Seet Ju Ee, 
according to the extent of inflammation in the lungs. The scoring system utilised was 
as follows: 0: Normal lungs; 1: Bronchiolitis only, not affecting surrounding alveoli; 
2: Bronchiolitis and peribronchiolar alveolitis; 3: Bronchiolitis and alveolitis affecting 
airspaces away from bronchioles, patchy, <50%; 4: Bronchiolitis and alveolitis 
affecting airspaces away from bronchioles, patchy, >50%; 5: Bronchiolitis and 
alveolitis affecting airspaces away from bronchioles, diffuse,  >50%. The scores for 
both control groups of uninfected mice were 0, which was expected as the mice were 
not inoculated with virus and no inflammation should be present. The score for the 
infected group of mice culled at day 3 post-infection was on average 2.5, which 
exhibited bronchiolitis and less diffused alveolitis. For infected group of mice culled 
at day 6 post-infection, the inflammation was more severe and scoring was increased 









athologsues of mice extrateds 3 and                                                                            
Figure 4.5. Hematoxylin and Eosin staining of formalin-fixed mice lungs. 
Representative images of each group were taken at 100X magnification (A, C, E, G) 
and 400X magnification (B, D, F, H). A and B: Lung tissues from control mice at Day 
3 timepoint. C and D: Lung tissues from control mice at Day 6 timepoint. E and F: 
Lung tissues from infected mice at Day 3 timepoint; G and H: Lung tissues from 
infected mice at Day 6 timepoint. Br: Bronchioles. * shows protein leakage into the 






























Figure 4.6. Histopathological scores in formalin-fixed lung tissue sections. 
Formalin-fixed lung tissue sections were sent to Department of Pathology, National 
University Hospital for microtome sectioning and Hematoxylin and Eosin (H & E) 
staining. Stained sections were observed under a light microscope at 100X 
magnification by a trained histopathologist, Dr Seet Ju Ee, and scored according to 
extent of inflammation in the lungs. Error bars represent SEM of the animals in each 
group (Control: n=6, Infected: n=10). 0: Normal; 1: Bronchiolitis only, not affecting 
surrounding alveoli; 2: Bronchiolitis and peribronchiolar alveolitis; 3: Bronchiolitis 
and alveolitis affecting airspaces away from bronchioles, patchy, < 50%; 4: 
Bronchiolitis and alveolitis affecting airspaces away from bronchioles, patchy, > 50%; 






























P < 0.01 
P < 0.01 
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4.1.6  Myeloperoxidase (MPO) assay in mice lung homogenates 
Figure 4.7 shows the MPO activity present in lung homogenate obtained from control 
mice and infected mice, as determined by MPO assay. The MPO activity is 
quantitative of the neutrophil infiltration in that lung sample (Graff et al, 1998). 
Myeloperoxidase activity in infected mice lung homogenates increased significantly 
in both days 3 and 6 post-infection, as compared to control lung homogenates. On day 
3 post-infection, MPO activity in infected samples increased to 71.9 units/mg from 
40.2 units/mg in control samples while on day 6-post infection, MPO activity rose 
from 53.3 units/mg in control samples to 110.1 units/mg in infected samples.  
 
4.1.7 Real-Time PCR analysis of gelatinases gene expression in lung tissues 
Gene expression levels of MMP-2 and MMP-9 were analyzed by Real-time PCR and 
normalized to gene expression levels of housekeeping gene β-actin. This was then 
expressed with respect to control uninfected mice to observe the effects of  the virus 
at day 3 and day 6 post-infection timepoint. In the infected groups of mice, MMP-2 
gene expression on day 6 post-infection increased significantly by 9.5 fold, as 
compared to control uninfected mice (Figure 4.8A). Upregulation of MMP-9 gene 
expression was even more pronounced in these infected groups on day 6 post-
infection, of which the fold change was 13.5 fold relative to control mice (Figure 
4.8B). On day 3 post-infection, no statistically significant increase in MMP-2 and 









Figure 4.7. Measurement of myeloperoxidase (MPO) activity in mice lung 
homogenate, expressed as Units/mg protein. MPO activities were normalised to 
protein concentrations of the lung homogenates, to account for the varying sizes of 
lung tissues used for homogenization. White bars represent control uninfected mice 
while black bars represent infected mice. Error bars represent SEM of the animals in 

































P < 0.05 




Figure 4.8 (A). Graph summarizing the fold change of gene expression levels of 
the MMP-2 gene. Data above was analyzed by real-time PCR. Gene expression of 
MMP-2 was normalized to gene expression levels of housekeeping gene β-actin. This 
was then expressed with respect to control uninfected mice to observe the effects of  
the virus at day 3 and day 6 post-infection timepoint. Error bars represent SEM of the 
animals in each group (Control: n=6, Infected: n=10). *Statistically significant p-
value < 0.05 as compared to control uninfected mice  
 
 
Figure 4.8 (B). Graph summarizing the fold change of gene expression levels of 
the MMP-9 gene. Data above was analyzed by real-time PCR. Gene expression of 
MMP-9 was normalized to gene expression levels of housekeeping gene β-actin. This 
was then expressed with respect to control uninfected mice to observe the effects of  
the virus at day 3 and day 6 post-infection timepoint. Error bars represent SEM of the 
animals in each group (Control: n=6, Infected: n=10). *Statistically significant p-


















Fold change of MMP-9 gene in infected mice 
















Fold change of MMP-2 gene in infected mice 





4.1.8 Western Blot analysis of gelatinases protein levels in BALF  
To evaluate the effect of influenza A/Aichi/2/68 (H3N2) P10 virus on secreted MMP-
2 and MMP-9 protein expression, western blot was done on the BALF samples from 
control and infected mice. With reference to figures 4.9A and 4.9B, our results 
revealed a significant increase in the protein expressions of both MMP-2 and MMP-9 
in infected BALF samples at the day 3 and day 6 post-infection timepoints. 
Densitometric analyses of the bands for MMP-2 and MMP-9 protein expression on 
day 3 post-infection showed a 1.8 fold and 1.6 fold increase respectively, as compared 
to control uninfected samples. On day 6 post-infection, MMP-2 and MMP-9 protein 
expressions were increased by 3.6 and 1.7 fold respectively (Figure 4.9C). 
 
4.1.9 Gelatinase zymography analysis of gelatinases protein activity in BALF 
Gelatinase zymography is an electrophoretic technique used to identify gelatinolytic 
activity in enzymes such as MMP-2 and MMP-9, separated in polyacrylamide gels 
under non-reducing conditions. The gels are stained in Coomassie blue and presence 
of gelatinases is depicted as clear zones, as a result of the digestion of the gelatin 
substrate present in the gels (Snoek-van Beurden and Von den Hoff, 2005). Figure 
4.10A shows a significant increase in gelatinolytic activity of MMP-9 present in 
infected BALF samples on day 3 post-infection, as compared to control samples. At 
this timepoint, MMP-2 activity is absent in infected samples. With reference to figure 
4.10B, we observed a significant increase in gelatinolytic activity of both MMP-2 and 














Figure 4.9. Western blot analysis depicting MMP-2 and MMP-9 protein 
expression in mice BALF samples. (A) Blots from control and infected mice culled 
on day 3 post-infection (B) Blots from control and infected mice culled on day 6 post-
infection. Lanes 1 and 2 represent two independent control samples; Lanes 3 and 4 
represent two independent infected samples. Pictures are representative of all animals 
within the group. (C) Densitometric analyses of Western blot bands, each expressed 
as a percentage of the control uninfected BALF samples, which is denoted as 100%. 
White bars represent control mice while black bars represent infected mice. Error bars 




























P < 0.01 
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Figure 4.10. Gelatinase Zymography analysis depicting MMP-2 and MMP-9 
protein activity in mice BALF samples. (A) Gels obtained from control and infected 
mice culled on day 3 post-infection (B) Gels obtained from control and infected mice 
culled on day 6 post-infection. Lanes 1 and 2 represent two independent control 
samples while 3 and 4 represent two independent infected samples. Pictures are 




















4.1.10 Cytopathic effect (CPE) of LA-4 cells 
Presence of viruses often gives rise to morphological changes in the host cell, and 
detectable changes are known as cytopathic effects (CPE), which consists of cell 
rounding, disorientation, death, shrinking, detachment from surface and more 
(Scholtissek et al, 1967). From figure 4.11, at timepoints 0h and 12h post-infection, 
both control cells and cells infected with Influenza A/Aichi/2/68 (H3N2) P10 virus 
showed similar morphology and there was absence of CPE. At 24h post-infection, 
infected cells start to show a little CPE and CPE was even more apparent at the 48h 
post-infection timepoint, in which the infected cells displayed rounding, shrinking and 
started detaching from the surface, in comparison to the control cells.  
 
4.1.11 Classical PCR to detect virus presence in LA-4 cells 
As seen from figure 4.12A, lanes 1 to 8 represent control samples across timepoints 
0h, 12h, 24h and 48h post-infection. These control samples consist of RNA from 
uninfected LA-4 cells and had no detectable bands, thus indicating that there was no 
amplification of viral PA2 gene due to the absence of the virus. Lane 9 represents the 
positive control, which helps us eliminate the possibility of false negatives. In figure 
4.12B, lanes 1 to 8 represent infected samples, consisting of RNA from infected LA-4 
cells, across timepoints 0h, 12h, 24h and 48h post-infection. Amplification of viral 
PA2 gene is apparent from the bands present in the 1% agarose gel for all the 




4.1.12 Virus titres of supernatant from LA-4 cells determined by plaque assay 
Figure 4.13 shows the virus titres of supernatant obtained from control and infected 
LA-4 cells at timepoints 0h, 12h, 24h and 48h post-infection, as determined by plaque 
assay using MDCK cells. Control samples for all the timepoints showed no plaques at 
all, thus indicating absence of virus. The single control bar in figure 4.13 represents 
the control samples for all timepoints. Virus titres of infected samples obtained at 12h, 
24h and 48h post-infection increased significantly to 7.8 X 10
4
 pfu/ml, 4 X 10
5 
pfu/ml 
and 6.5 X 10
5 
pfu/ml respectively, as compared to infected samples obtained at the 0h 
timepoint. This not only shows the presence of influenza virus in the LA4 cells, but 


































































Figure 4.11. Cytopathic effect (CPE) observed in LA-4 alveolar epithelial cells. 
Left panel represents control uninfected cells and right panel represents infected cells. 
























Figure 4.12. 1% agarose gel electrophoresis of PCR amplified viral PA2 gene of 
Influenza A/Aichi/2/68 strain. (A) Gel of control uninfected samples (B) Gel of 
influenza virus-infected samples. Lane MW represents the 100 bp DNA ladder. Lanes 
1 and 2 represent 0h samples; Lanes 3 and 4 represent 12h samples; Lanes 5 and 6 






Figure 4.13. Virus titres of supernatant obtained from LA-4 cells, expressed in 
pfu/ml. Values were obtained by performing plaque assay where supernatant from 
LA-4 cells were used to infect MDCK cells. Control bar is representative of all 
control samples for 0h, 12h, 24h and 48h timepoints. Error bars represent SEM of the 
samples in each group.  
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4.1.13 Real-Time PCR analysis of gelatinases gene expression in LA-4 cells 
Gene expression levels of MMP-2 and MMP-9 were analyzed by Real-time PCR and 
normalized to gene expression levels of housekeeping gene β-actin. This was then 
expressed with respect to control LA-4 cells to observe the effects of  the virus at 0h, 
12h, 24h and 48h post-infection timepoints. In the infected group of samples, MMP-2 
gene expression decreased significantly by 4.6 fold and 13 fold for 24h and 48h post-
infection timepoints respectively, as compared to control uninfected cells (Figure 
4.14A). Upregulation of MMP-9 gene expression was observed in infected cells at 
12h, 24h and 48h post-infection, of which the fold changes were 3.0 fold, 6.6 fold and 
3.9 fold, relative to control cells. A slight but significant decrease of 1.2 fold of 




























Figure 4.14 (A). Graph summarizing the fold change of gene expression levels of 
the MMP-2 gene. Data above was analyzed by real-time PCR. Gene expression of 
MMP-2 was normalized to gene expression levels of housekeeping gene β-actin. This 
was then expressed with respect to control cells to observe the effects of the virus at 
0h, 12h, 24h and 48h post-infection timepoint. Error bars represent SEM of the 
samples in each group. *Statistically significant p-value < 0.05 as compared to control 
cells  
 
Figure 4.14 (B). Graph summarizing the fold change of gene expression levels of 
the MMP-9 gene. Data above was analyzed by real-time PCR. Gene expression of 
MMP-9 was normalized to gene expression levels of housekeeping gene β-actin. This 
was then expressed with respect to control cells to observe the effects of the virus at 
0h, 12h, 24h and 48h post-infection timepoint. Error bars represent SEM of the 
samples in each group. *Statistically significant p-value < 0.05 as compared to control 
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Fold change of MMP-9 gene in infected cells 









4.1.14 Western Blot analysis of gelatinases protein levels in LA-4 cells  
To evaluate the effects of influenza A/Aichi/2/68 (H3N2) P10 virus on secreted 
MMP-2 and MMP-9 protein expression, western blot was done on the supernatant 
obtained from LA-4 cells. With reference to figures 4.15A, our results revealed a 
significant increase in the protein expression of MMP-2 in infected LA-4 cells at 24h 
and 48h post-infection timepoint while protein expression of MMP-9 in infected LA-4 
cells were upregulated only at 48h post-infection. Densitometric analyses of the bands 
showed a 1.4 fold and 1.6 fold increase in MMP-2 protein expression at 24h and 48h 
post-infection respectively, as compared to control uninfected samples (Figure 
4.15B). At 48h post-infection, a 2 fold increase in MMP-9 protein expression was 
observed in infected LA-4 cells, relative to control cells (Figure 4.15C).  
 
4.1.15 Gelatinase zymography of gelatinases protein activity in LA-4 cells  
Figure 4.16A shows a significant increase in gelatinolytic activity of both MMP-2 and 
MMP-9 present in supernatant obtained from infected LA-4 cells at 48h post-
infection, as compared to control samples. With reference to figure 4.16B, 
gelatinolytic activity of MMP-2 increased by 1.9 fold in infected LA-4 cells, as 
compared to control cells. With reference to figure 4.16C, gelatinolytic activity of 
























Figure 4.15. Western blot analysis depicting MMP-2 and MMP-9 protein 
expression in supernatant of LA-4 cells. (A) Blots obtained from control and 
infected cells at 0h, 12h, 24h and 48h post-infection. Lanes 1, 2, 3 and 4 represent 
control samples obtained from 0h, 12h, 24h and 48h post-infection timepoints 
respectively while lanes 5, 6, 7 and 8 represent infected samples obtained from 0h, 
12h, 24h and 48h post-infection timepoints respectively. (B) Densitometric analyses 
of MMP-2 Western blot bands, expressed as a percentage of the control cells at that 
timepoint, which is denoted as 100%. (C) Densitometric analyses of MMP-9 Western 
blot bands, expressed as a percentage of the control cells at that timepoint, which is 
denoted as 100%. White bars represent control uninfected cells while black bars 
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Figure 4.16. Gelatinase Zymography analysis depicting MMP-2 and MMP-9 
protein activity in supernatant of LA-4 cells. (A) Gels obtained from control and 
infected cells at 0h, 12h, 24h and 48h post-infection. Lanes 1, 2, 3 and 4 represent 
control samples obtained from 0h, 12h, 24h and 48h post-infection timepoints 
respectively while lanes 5, 6, 7 and 8 represent infected samples obtained from 0h, 
12h, 24h and 48h post-infection timepoints respectively. (B) Densitometric analyses 
of MMP-2 gelatinase zymographic bands, expressed as a percentage of the control 
cells at that timepoint, which is denoted as 100%. (C) Densitometric analyses of 
MMP-9 gelatinase zymographic bands, expressed as a percentage of the control cells 
at that timepoint, which is denoted as 100%. White bars represent control uninfected 
cells while black bars represent infected cells. Error bars represent SEM of the 
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4.2  DISCUSSION 
4.2.1  Expression of MMPs in influenza pneumonitis  
Influenza pneumonitis has always been a considerable concern as it is associated with 
substantial morbidity and mortality. Inflammation of the lung, particularly 
recruitment and activation of neutrophils, could lead to acute lung injury (ALI) or in 
more severe cases, acute respiratory distress syndrome (ARDS) (Yokoyama et al, 
2010). Neutrophils are an abundant source of reactive oxygen species and proteolytic 
enzymes including neutrophil elastase and matrix metalloproteinases, which 
consequentially lead to destruction of alveolar microvascular bed. When the alveolar-
capillary barrier is disrupted, plasma proteins, edema fluid and inflammatory 
exudates leak into the interstitium and alveolar airspace and compromise the lung‘s 
normal physiological function (Bdeir et al, 2010; Fingleton, 2007; Quispe-Laime et 
al, 2010). Previous work in our lab had established a mouse adaptation model 
through serial lung-to-lung passaging, of which the mouse-adapted influenza 
A/Aichi/2/68 (H3N2) passage 10 (P10) virus caused severe pneumonitis and broad 
tissue tropism in the host (Narasaraju et al, 2009). Transcriptomic analysis of severe 
murine pneumonitis induced by this mouse-adapted P10 virus, using microarray and 
real-time quantitative PCR, revealed an upregulation in gene expression of members 
of the MMP family, including MMP-3, MMP-8, MMP-9, MMP-13 and MMP-14, a 
protein involved in activation of MMP-2, at the 96h post-infection timepoint 
(Unpublished data) (Figure 4.1). In light of current evidence that gelatinases MMP-2 
and MMP-9 degrade collagen IV, a major component of the basement membrane, we 
hypothesize that these proteases might be crucial in initiating the development of host 
lung injury during influenza virus infection. Hence, in this study, we investigated the 
effect of a mouse-adapted Influenza A/Aichi/2/68 (H3N2) P10 virus on the protein  
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expression of these gelatinases, MMP-2 and MMP-9 in an in vivo murine model of 
influenza pneumonitis to better understand the virus-host cell interaction. 
 
4.2.2 Mouse-adapted Influenza A/Aichi/2/68 P10 (H3N2) virus infection in 
mice. 
Definitive clinical symptoms are necessary for the evidence of virus infection and the  
initial determination of disease in mice and in the case of influenza virus infection, 
weight loss serves as a gross indicator of morbidity of mice (Bantia, Parker et al. 
2001; Belser, Szretter et al. 2009). Animals generally lose weight when they are ill 
because they have decreased appetites and feed much less, although food and water 
were provided ad libitum. Hence, average percentage weight loss in mice would serve 
as an indicator of morbidity in mice. As seen from section 4.1.2, figure 4.2 showed us 
that the control groups of uninfected mice which were culled at day 3 and day 6 post-
infection displayed no weight loss and had average weights of (102 ± 2.44)% and 
(103 ± 2.97)% respectively, when expressed as a percentage relative to their initial 
weights on day 0. The gain of weights in both control groups is an indication of 
absence of gross morbidity, and in this context, suggestive of the lack of influenza 
infection. Mice inoculated with Influenza Passage 10 (P10) virus and euthanized on 
day 3 and day 6 post-infection on average weighed only (87.1 ± 1.96)% and (77.8 ± 
2.28)% of their average initial weights respectively. Futhermore, clinical observations 
such as ruffled fur, lethargy and laboured breathing were observed in infected mice 
from both groups, which were indicative of respiratory disease. These manifestations 
suggested impaired respiratory functions in mice which is due to the mouse-adapted 
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virus infection, and the augmented weight loss at the later day 6 post-infection 
timpoint suggests more severe disease progression which may develop into serious 
post-infection sequelae. 
 
Confirmation of virus infection in mice was further validated by plaque assay and 
immunohistochemical staining of lung tissue sections. Animals from the control 
uninfected group showed no virus at all in both plaque assay and 
immunohistochemistry, which is expected because they were not exposed to the virus 
and were housed separately from infected mice at all times (Figure 4.3 and Figure 
4.4). Comparing across time points, virus titre was higher in influenza virus-infected 
mice on day 3 post-infection than on day 6 post-infection. This observation is in line 
with the knowledge that influenza virus titres generally peak within the first 2 to 3 
days post-infection and titres start to decline therafter, as seen on day 6. The decline 
of virus titre is due to the activation of the host immune system upon influenza virus 
infection, which contributes to viral clearance (Baccam et al, 2006). In agreement 
with plaque assay, immunohistochemistry staining showed widespread positive 
staining for virus antigen in the lungs of the P10 virus-infected group culled on day 3 
post-infection. This suggests that the mice were indeed infected with the virus and the 
virus may have acquired broad cell tropism upon infection. Lungs of the P10 virus-
infected group culled on day 6 post-infection showed positive staining for virus but 
staining was less diffused and restricted to the bronchiolar epithelium. Less 
widespread virus staining may be attributed to viral clearance, thus less virus is 
present in the later timepoint. 
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4.2.3 Mouse-adapted Influenza A/Aichi/2/68 P10 (H3N2) virus causes 
productive replication in LA4 cells. 
Presence of viruses often gives rise to morphological changes in the host cell, and 
detectable changes are known as cytopathic effects (CPE), which consists of cell 
rounding, disorientation, death, shrinking, detachment from surface and more 
(Scholtissek et al, 1967). LA4 lung epithelial cells have been used previously, in vitro 
models for influenza virus infection and Reading et al has shown that influenza 
viruses have the ability to infect LA4 cells, replicate in them, and release newly 
synthesized virions (Shinya et al, 2007; Szretter et al, 2009). In our study, section 
4.1.10 and figure 4.11 shows that infected cells displayed CPE at the later timepoints, 
24h and 48h post-infection, confirming virus infection of the murine alveolar 
epithelial LA4 cells. In concert with CPE observation at later timepoints, plaque assay 
illustrates an increase in virus titre from 0h to 48h post-infection in supernatant 
obtained from infected LA4 cells (Figure 4.13). The significant elevation in virus titre 
at later timepoints explains CPE formation at the later phases of influenza infection. 
Besides providing evidence of virus infection, the increase in virus titre also suggests 
LA4 alveolar epithelial cells as good hosts for replication of influenza virus. 
 
4.2.4 Evaluation of acute lung injury in mice infected with the mouse-adapted 
Influenza A/Aichi/2/68 P10 (H3N2) virus 
As cited by Kash et al, 2004, severe influenza infections are associated with 
morphological changes in alveolar cells, exemplified by acute alveolitis, and the onset 
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of severe inflammation and bronchitis within days of infection. Our lab group had 
previously established a mouse adaptation model of which a lethal dose of the mouse-
adapted influenza A/Aichi/2/68 (H3N2) P10 virus caused severe pneumonitis and 
broad tissue tropism in the host (Narasaraju et al, 2009). In the present study, we 
utilized a sub-lethal dose of the mouse-adapted P10 virus to infect mice and the lungs 
exhibited mild penumonitis on day 3 post-infection, in which mostly inflammation of 
bronchioles were observed, along with inflammation in alveolar regions surrounding 
the bronchioles. On day 6 post-infection, the lung lesions deteriorated to more severe 
and widespread penumonitis, accompanied by leakage of protein into the airspaces 
and congestion of alveolar spaces, which were the probable causes of asphyxiation 
that led to the observation of laboured breathing in mice. Hyperplasia of the 
bronchioles was also seen at this timepoint, as seen by the thickened bronchial 
columnar epithelial cells, indicative of cell proliferation in response to damage caused 
by the infection. At both timepoints, majority of the infiltrates were mononuclear 
macrophages and fewer neutrophils were present. According to Taubenberger and 
Morens, 2008, infiltration of neutrophils during influenza virus infection is never 
massive in the absence of a secondary bacterial infection, as compared to 
macrophages. However, neutrophil infiltration is still considered as one of the 
characteristic features of influenza virus infection and the increase in 
myeloperoxidase assay for both day 3 and day 6 post-infection timepoints is 
indicative of neutrophil activity upon viral infection. We have thus demonstrated that 




4.2.5 Increase in MMPs expression and activity and their role in influenza 
virus-induced host lung injury  
In the recent years, Influenza and MMPs have been more extensively researched on 
and in particular, gelatinases MMP-2 and MMP-9 have elicited interest in many due 
to their imperative role in degrading the basement membrane. Though it is apparent 
that a link between influenza and these proteases exist, the role of MMPs in influenza 
virus infection is still not well elucidated. Previously, Yeo et al investigated the effect 
of influenza A/Beijing/353/89 (H3N2) virus infection on the expression of MMP-2 
and -9 in two epithelial cell lines: Vero cells and MDCK cells. Upon virus infection, 
the expression of MMP-9 but not MMP-2 was stimulated in Vero cells. However, in 
MDCK cells, only MMP-2 production was increased. The modulation of gelatinases 
thus seems to be dependant on the epithelial cell line. In this present study, we report 
an increase in both MMP-2 and MMP-9 protein expression and activity in vitro when 
we infected LA4 murine alveolar epithelial cells with influenza A/Aichi/2/68 (H3N2) 
P10 virus. MMP-2 protein expression was increased at 24h and 48h post-infection 
timepoints, as revealed by western blot analysis, while activity of the protein was 
increased at the 48h timepoint, as shown by gelatinase zymography (Figure 4.15 and 
Figure 4.16). MMP-9 protein expression and gelatinolytic activity was upregulated at 
48h post-infection. The results demonstrate alveolar epithelial cells as a source of 
secreted gelatinases during influenza virus infection and this is not atypical for MMP-
2 since it has been established to be synthesized by a wide variety of cells, including 
alveolar epithelial cells (Murphy and Docherty, 1992; Yao et al, 1997). MMP-9, on 
the other hand, is produced mainly by inflammatory cells such as neutrophils but 
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under certain conditions such as injury or stress, other cell types including alveolar 
epithelial cells have the ability to produce MMP-9 as well (Buisson et al, 1996). The 
ability of lung epithelial cells to produce MMP-9 has been previously demonstrated in 
human bronchial epithelial cells (Legrand et al, 1999; Yao et al, 1996). In the present 
study, the baseline gelatinase activity in control LA-4 cells at the 12h post-infection 
timepoint may be attributed to stress on the epithelial cells when medium and trypsin 
were added. Stress is one of the factors that may induce gelatinase expressions at 
initial timepoints, but the virus infection induced MMP expression to a greater extent 
at later timepoints. At the transcriptional level, MMP-2 gene expression decreases 
overtime while MMP-9 gene expression increases, as denoted by quantitative real-
time PCR (Figure 4.14). The difference in gene expressions of both gelatinases might 
be attributed to their marked difference with regard to transcriptional control by 
regulatory mechanisms, as reported in Huhtala et al, 1991. The increased gene 
expression of MMP-9 in influenza virus-infected cells seemed to demonstrate a 
transcriptional response to the viral infection for this gene and is reflective in the 
increase in protein expression. MMP-2 gene expression, however, decreases while the 
protein expression increases in infected cells. One possible reason might be due to the 
long half life of the secreted MMP-2 protein, which causes it to accumulate in the 
supernatant and thus resulting in a negative feedback to reduce the amount of gene 
expression (Ben-Yosef et al, 2005).  
 
The authors of Yeo et al, 1996 suggest two possible implications of an increased 
gelatinase expression in influenza virus-infected epithelial cells: Host defense 
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mechanism or destructive mechanism. The former is in the hopes of limiting viral 
spread as during the infective cycle, the infected host cells may be detached from the 
epithelial monolayer and basement membrane by abundant proteolytic activity, to 
prevent entry into the deeper tissues. The latter, on the other hand, suggests the 
accumulated pericellular proteolytic activity may lead to the disruption of basement 
membrane and underlying stroma, allowing viruses to invade deep tissues where 
blood vessels and lymphatics are distributed. Several extrapulmonary conditions 
associated with influenza A virus infections such as viremia, encephalopathy and 
myocarditis supports the possibility of accumulation of MMPs which disrupts the 
basement membrane to allow widespread viral injury (Ichiyama et al  ¸2007; Mori et 
al, 1995; Ray et al, 1989). A most recent paper, Wang et al  ¸2010, identified a marked 
upregulation of MMP-9 and tumor necrosis factor alpha (TNF-α) in various organs 
upon Influenza A/WSN/33 (H1N1) infection of C57BL/6 mice. MMP-9 activities 
were elevated in the damaged lung, brain and heart tissues and type IV collagen, a 
specific substrate of MMP-9, largely disappeared upon the upregulation of MMP-9. 
This study further confirms a possible role of MMP-9 in extrapulmonary 
pathogenicity during influenza virus infection. Cell-based models are adequate in 
providing insights into differential gene expression during pathogenesis resulting 
from alteration of intracellular signalling cascades and transcription machinery, and 
increased MMPs expression in LA4 cells indicates alveolar epithelial cells as a source 




In our study, we report an increase in both MMP-2 and MMP-9 gene and protein 
expressions in vivo when we infected BALB/C mice with influenza A/Aichi/2/68 
(H3N2) P10 virus. Gene expression of both gelatinases increased significantly on day 
6 post-infection timepoint (Figure 4.8). MMP-2 protein expression was increased on 
days 3 and 6 post-infection, as revealed by western blot analysis but gelatinase 
zymography showed increase in MMP-2 gelatinolytic activity at the day 6 timepoint 
only (Figure 4.9 and Figure 4.10). MMP-9 protein expression and gelatinolytic 
activity were upregulated on both day 3 and day 6 post-infection. The results were 
similar to previous studies utilizing influenza murine models in which Gualano et al, 
2008 reported an increase in both MMP-2 and MMP-9 upon influenza A/Mem71 
(H3N1) virus infection of BALB/c mice on day 3 post infection while Dessing et al, 
2009 observed increase in MMP-2 gene expression in an influenza pneumonia murine 
model. In Wang et al, 2010, the authors reported that upon influenza A WSN Virus 
infection, MMP-9 expression was increased. It was shown that influenza causes the 
upregulation of TNF-α, which stimulates MMP-9 in mice via mitogen activated 
protein kinase-nuclear factor kappa B (MAPK-NFĸB) and activator protein 1 (AP-1)-
dependant mechanisms.  
 
It is clear from our study that inflammation of the lung during influenza virus 
infection, as seen from histopathology images and MPO assay, is associated with the 
increase in gelatinase expression. The increased concentration of MMP-9 might be 
induced by the elevated levels of activated neutrophils in the respiratory tract because 
MMP-9 is found in neutrophils and its levels have been significantly correlated with 
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the increase in the number of neutrophils in the lung (Masure et al, 1991; Ricou et al, 
1996; Torii et al, 1997). Furthermore, neutrophils have been shown previously to 
secrete MMP-2 as well (Fligiel et al, 2006). Besides neutrophils, activated 
macrophages can synthesise de novo MMP-2 and MMP-9 and these proteinases have 
been associated to play a role in macrophage-dependant acute lung injury 
(Chakrabarti et al, 2006; Gibbs et al, 1999). Yoo et al  ¸2002 reported the upregulation 
of MMP-9 expression via production of reactive oxygen species and activation of 
nuclear factor kappa B (NFĸB) in RAW 264.7 macrophage cell line. In addition, from 
our in vitro model, resident cells in the lung parenchyma including alveolar epithelial 
cells have been shown to be another possible source for both gelatinases during 
influenza virus infection, thus contributing to increased expression of the gelatinases. 
Mauviel, 1993 and Warner et al, 2004 suggest the secretion of gelatinases by alveolar 
epithelial cells to be due to either proinflammatory mediators released from activated 
alveolar macrophages or directly by proinflammatory products such as immune 
complexes. Oxidative stress seems to be another factor that could increase MMP-2 
and MMP-9 expressions in type II alveolar cells in rats (Pardo et al, 1998).  
 
A possible significance of increased gelatinase expression in mice upon influenza 
virus infection is the pathological role of MMP-2 and MMP-9 in host lung injury. The 
accumulated proteolytic activity of MMP-2 and MMP-9 results in increased damage 
to pulmonary epithelium and endothelium due to degradation of the basement 
membrane, which is an essential first step to host lung injury. Disruption of the 
alveolar-capillary barrier which results could be followed by protein leakage, 
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pulmonary edema and pneumonia, thus leading to the development of ALI and more 
severely, ARDS. Previous studies have shown that the extent of basement membrane 
digestion by accumulated pericellular proteolytic activity of gelatinases is a 
significant factor in determining disease outcome in ARDS and in patients suffering 
from ALI and ARDS, degradation products of type IV collagen have been found in 
alveolar spaces and BALF samples contain highly elevated gelatinases (Corbel et al, 
2000; O‘Connor and FitzGerald, 1994). Thus, MMP-2 and MMP-9 play a vital role in 
initiating ARDS development, a severe complication of influenza virus infection. 
 
4.3 CONCLUSION 
From our in vitro and in vivo studies, we observed an increase in gelatinases MMP-2 
and MMP-9 upon influenza A/Aichi/2/68 (H3N2) P10 virus infection in a murine 
pneumonitis model. The acute inflammatory response elicited by virus infection 
results in activation of neutrophils and macrophages, which are sources of gelatinases. 
In addition, resident alveolar epithelial cells in the lung also contribute to the 
production of gelatinases during viral infection. The host reponse to increase 
expression of gelatinases has a pathological significance in host lung injury through 
pulmonary damage and suggests a contribution to post-infection sequelae of influenza 
virus infection. Figure 4.17 summarises this pathological role of MMPs, in particular 
the gelatinases, in influenza-induced host lung injury. The data outlined in our study 
implicates excess MMP activity in the pathogenesis of influenza and thus, modulation 
of MMP activity may reduce immunopathology and might be an important approach 





















Figure 4.17. Schematic diagram of the contribution of MMPs in influenza virus-
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CHAPTER 5: EFFECTS OF DOXYCYCLINE ON INFLUENZA-INDUCED 
INFLAMMATION AND HOST LUNG INJURY  
 
5.1  RESULTS 
5.1.1 Average weight of mice   
The weights of the mice were monitored daily and measured every 24h, from the first 
day of doxycycline (DOX) treatment (Day -3) to the day of Influenza A/Aichi/2/68 
(H3N2) P10 virus administration (Day 0) to the day of euthanization, at day 6 post-
infection (Day 6). The three control groups of mice, namely the uninfected mice 
treated with water, uninfected mice treated with 20mg/kg DOX and uninfected mice 
treated with 60mg/kg DOX, showed minimal weight loss at the point of euthanization 
and had average weights of (97.9 ± 0.82)%, (99.8 ± 3.94)% and (100.2 ± 3.05)% 
respectively, when expressed as a percentage relative to their initial weights on day 0 
(Figure 5.1). The group of infected mice treated with water in replacement of DOX, 
showed an average weight of (82.3 ± 4.17)% while the infected mice treated with the 
two doses of DOX showed even more marked decrease in weights. The groups of 
infected mice treated with 20mg/kg DOX and 60mg/kg DOX, showed average 
weights of (79.4 ± 6.77)% and (80.4 ± 5.54)% respectively, when expressed as a 











Figure 5.1. Average weights of mice from 3 days before virus administration to 6 
days post-infection. Day -3 marks the first day of doxycycline (DOX) treatment. Day 
0 marks the first day of infection of mice with either Influenza A/Aichi/2/68 (H3N2) 
P10 virus or uninfected lung homogenate as a control. Day 6 marks the sixth day upon 
virus infection, at which the mice are euthanized. Weights are expressed as a 
percentage of the average weight of the individual groups on day 0. Error bars 
represent SEM of the animals in each group (Control: n=4, Control + 20mg/kg DOX: 
n=4, Control + 60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, 
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5.1.2 Western Blot analysis of gelatinases protein levels in BALF  
To evaluate the effects of doxycycline (DOX) treatment on secreted MMP-2 and 
MMP-9 protein expression upon influenza A/Aichi/2/68 (H3N2) P10 virus infection, 
western blot was done on the BALF samples obtained from control and infected mice, 
with or without treatment of DOX. With reference to figure 5.2A, our results revealed 
a significant reduction in the protein expression of both MMP-2 and MMP-9 in BALF 
samples obtained from infected mice treated with the two doses of DOX, as compared 
to the group of infected mice treated with water. Densitometric analyses of the bands 
showed a 1.4 fold reduction in both gelatinases expression in 20mg/kg DOX and 
60mg/kg treated groups of infected mice, as compared to infected samples treated 
with water instead of DOX (Figure 5.2B).  
 
5.1.3 Gelatinase zymography analysis of gelatinases protein activity in BALF 
Figure 5.3A shows a significant decrease in gelatinolytic activity of both MMP-2 and 
MMP-9 present in BALF samples obtained from infected mice treated with both 
doses of DOX, as compared to the solvent control group of infected mice treated with 
water. No bands were detected for the three control groups of uninfected mice. With 
reference to figure 5.3B, densitometric analyses of the bands showed a 1.7 fold and 
2.1 fold reduction in MMP-9 protein expression and a 2.3 fold and 3.3 fold reduction 
in MMP-2 protein expression in 20mg/kg DOX and 60mg/kg treated groups of 
infected mice respectively, as compared to the group of infected mice treated with 






















Figure 5.2. Western blot analysis depicting MMP-2 and MMP-9 protein 
expression in mice BALF samples upon Doxycycline (DOX) treatment. (A) Blots 
obtained from mice BALF samples. Lanes 1 and 2 represent two independent control 
samples; Lanes 3 and 4 represent two independent infected samples; Lanes 5 and 6 
represent two independent infected samples treated with 20mg/kg DOX; Lanes 7 and 
8 represent two independent infected samples treated with 60mg/kg DOX. Pictures 
are representative of all animals within the group. (B) Densitometric analyses of 
Western blot bands, each expressed as the absolute intensity of the band. White bars 
represent control uninfected mice, black bars represent infected mice, light grey bars 
represent infected samples treated with 20mg/kg DOX and dark grey bars represent 
infected samples treated with 60mg/kg DOX. Error bars represent SEM of the animals 
in each group (Control: n=4, Control + 20mg/kg DOX: n=4, Control + 60mg/kg 
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Figure 5.3. Gelatinase Zymography analysis depicting MMP-2 and MMP-9 
protein activity in mice BALF samples upon Doxycycline (DOX) treatment. (A) 
Gels obtained from mice BALF samples. Lanes 1, 2 and 3 represent control samples 
of uninfected mice treated with water, uninfected mice treated with 20mg/kg DOX 
and uninfected mice treated with 60mg/kg DOX respectively; Lane 4 represents 
infected mice treated with water; Lane 5 represents infected mice treated with 
20mg/kg DOX; Lane 6 represents infected mice treated with 60mg/kg DOX. Pictures 
are representative of all animals within the group. (B) Densitometric analyses of 
gelatinase zymography bands, each expressed as the absolute intensity of the band. 
White bars represent control uninfected mice, black bars represent infected mice, light 
grey bars represent infected samples treated with 20mg/kg DOX and dark grey bars 
represent infected samples treated with 60mg/kg DOX. Error bars represent SEM of 
the animals in each group (Control: n=4, Control + 20mg/kg DOX: n=4, Control + 
60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, Infected + 
60mg/kg DOX: n=8). 
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5.1.4 Total inflammatory cell count in BALF 
Total inflammatory cell count in BALF was determined by the trypan blue exclusion 
method. With reference to figure 5.4, BALF samples from the control mice treated 
with water, control mice treated with 20mg/kg DOX and control mice treated with 
60mg/kg DOX contained low numbers of total inflammatory cell. These values were 
2.4 X 10
4 
cells, 2.3 X 10
4 
cells and 2.0 X 10
4 
cells respectively. Upon infection with 
Influenza A/Aichi/2/68 (H3N2) P10 virus, mice had massive increase in infiltration of 
inflammatory cells into the BALF. Infected group of mice treated with water had an 
average of 7.6 X 10
5 
inflammatory cells in their BALF and this was significantly 
reduced in infected groups treated with 20mg/kg DOX, which had an average of 4.9 X 
10
5 
cells in their BALF. Cellular infiltrates in BALF were further reduced in infected 
mice treated with 60mg/kg DOX, in which an average of 4.1 X 10
5
 inflammatory cells 
was present in the mice BALF samples (Figure 5.4). 
 
5.1.5 Differential inflammatory cell count in BALF  
Differential cell count of the cellular infiltrates in BALF samples was determined by 
giemsa staining. In all three control groups of mice, neutrophils were absent in BALF 
samples and the average number of macrophages in control mice, control mice treated 





, 1.8 X 10
4
 respectively. Lymphocytes in these samples were 2.3 X 10
3
, 2.3 X 
10
3
, 2.2 X 10
3
 respectively (Figure 5.5). Influenza A/Aichi/2/68 (H3N2) P10 virus 
caused significant increase in neutrophils, macrophages and lymphocytes in mice 




neutrophils in their BALF and DOX treatment decreased neutrophil levels to 9.1 X 
10
4 
and 7.9 X 10
4 
cells in 20mg/kg DOX and 60mg/kg DOX treated mice 
respectively. Similar trends were observed for both macrophages and lymphocytes, in 
which upon doxycycline treatment in influenza virus infection, average number of 
cells decreased significantly as compared to the infected group of mice treated with 
water. The average number of macrophages in infected mice, infected mice treated 





, 2.9 X 10
5
 respectively. Lymphocytes in these samples were 9.0 X 10
4
, 5.9 X 
10
4
, 3.9 X 10
4
 respectively (Figure 5.5). 
 
5.1.6  Myeloperoxidase (MPO) assay in mice lung homogenates 
Figure 5.6 shows the MPO activity present in lung homogenate obtained from control 
mice treated with water, control mice treated with 20mg/kg DOX, control mice 
treated with 60mg/kg DOX, infected mice treated with water, infected mice treated 
with 20mg/kg DOX and infected mice treated with 60mg/kg DOX, as determined by 
MPO assay. The MPO activity is quantitative of the neutrophil infiltration in that lung 
sample (Graff et al, 1998). Myeloperoxidase activity in infected mice lung 
homogenates increased significantly as compared to control lung homogenates. 
However, upon 60 mg/kg DOX treatment of infected mice, MPO activity decreased 
from 110.3 units/mg to 62.7 units/mg. The decrease to 70.5 units/mg in the infected 





Figure 5.4. Total number of inflammatory cells in mice BALF samples upon 
Doxycycline (DOX) treatment. Cells from all 3 control groups and 3 infected groups 
were counted using the trypan blue exclusion method. Error bars represent SEM of 
the animals in each group (Control: n=4, Control + 20mg/kg DOX: n=4, Control + 
60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, Infected + 
60mg/kg DOX: n=8). 
 
Figure 5.5. Differential cell count of inflammatory cell infiltrates in mice BALF 
samples upon doxycycline (DOX) treatment. Cells were counted using giemsa 
staining method. White bars represent polymorphonuclear neutrophils, black bars 
represent macrophages and light grey bars represent lymphocytes.Error bars represent 
SEM of the animals in each group (Control: n=4, Control + 20mg/kg DOX: n=4, 
Control + 60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, 
Infected + 60mg/kg DOX: n=8).**Statistically significant p-value < 0.01 as compared 
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Figure 5.6. Measurement of myeloperoxidase (MPO) activity in mice lung 
homogenate, expressed as Units/mg protein, upon doxycycline (DOX) treatment. 
MPO activities were normalised to protein concentrations of the lung homogenates, to 
account for the varying sizes of lung tissues used for homogenization. Error bars 
represent SEM of the animals in each group (Control: n=4, Control + 20mg/kg DOX: 
n=4, Control + 60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, 
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5.1.7 Virus titres of mice lung homogenates determined by plaque assay 
Figure 5.7 shows the virus titres of lung samples obtained from control mice treated 
with water, control mice treated with 20mg/kg DOX, control mice treated with 
60mg/kg DOX, infected mice treated with water, infected mice treated with 20mg/kg 
DOX and infected mice treated with 60mg/kg DOX, as determined by plaque assay 
using MDCK cells. Lung homogenates obtained from all three control groups showed 
no plaque formations, thus indicating absence of virus. Infected mice treated with 
water had virus titres of 4.2 X 10
3
 pfu/mg protein and this was significantly increased 
upon 60mg/kg DOX treatment, of which the virus titre was elevated by 4 fold to 1.6  
X 10
4 
pfu/mg protein. The virus titre for infected mice treated with 20mg/kg DOX 
was increased to 6.7 X 10
3
 pfu/mg protein, as compared to the solvent control group 
of infected mice, but the increase was not statistically significant.  
 
 
5.1.8 BALF protein concentrations 
Animals in the three control groups consistently showed low protein concentrations in 
BALF supernatant, with a range of 5.0 X 10
2
 to 7.0 X 10
2
 of protein. Upon infection 
with Influenza A/Aichi/2/68 virus, mice BALF protein content elevated to 3.2 X 10
3
 
µg/ml in infected mice treated with water. With reference to figure 5.8, when infected 
mice were treated with doxycycline (DOX), BALF protein concentrations reduced 
significantly to 2.1 X 10
3
 µg/ml and 1.8 X 10
3
 µg/ml in 20mg/kg DOX and 60mg/kg 






Figure 5.7. Virus titres of mice lung homogenates, expressed in pfu/mg protein, 
upon doxycycline (DOX) treatment. Values were obtained by performing plaque 
assay where filtered lung homogenates were used to infect MDCK cells. Virus titres 
were then normalised to protein concentrations of the lung homogenates, to account 
for the varying sizes of lung tissues used for homogenization. Error bars represent 
SEM of the animals in each group (Control: n=4, Control + 20mg/kg DOX: n=4, 
Control + 60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, 
Infected + 60mg/kg DOX: n=8). 
 
 
Figure 5.8. Graph showing protein concentration of BALF supernatant, 
expressed in µg/ml, upon doxycycline (DOX) treatment. BALF supernatant were 
analyzed by LowryHS protein estimation assay with a Beckman Coulter ® Du 640B 
spectrophotometer. Error bars represent SEM of the animals in each group (Control: 
n=4, Control + 20mg/kg DOX: n=4, Control + 60mg/kg DOX: n=4, Infected: n=8, 
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5.1.9 Histopathology of lung tissues of mice  
Figures 5.9A and 5.9B represent lung tissues obtained from control uninfected groups 
of mice. These images show bronchioles of normal thickness, made up of columnar 
epithelial cells, accompanied by normal, well-structured alveoli. All the airspaces 
were clear of infiltrates. Upon infection with mouse-adapted A/Aichi/2/68 (H3N2) 
P10 virus, pathologic lesions appear in lung tissue sections of the mice. Figures 5.9C 
and 5.9D represent lung tissues obtained from infected groups of mice treated with 
water instead of doxycycline (DOX). It is apparent from figure 5.9C that there was 
severe bronchiolitis (As indicated by the arrows) with massive inflammatory 
infiltrations in the alveolar region (As indicated by arrowheads). Bronchioles showed 
more prononunced hyperplasia, seen by the thickened columnar epithelial cells and 
loss of bronchiolar epithelium and diffused alveolar damage were also observed. A 
magnified view of the bronchioles was represented by figure 5.9D and extensive 
infiltration of both macrophages and neutrophils were observed in the air spaces of 
the bronchioles, accompanied by leakage of proteins, as indicated by the asterisk. 
Figures 5.9E and 5.9F show lung tissues obtained from infected groups of mice 
treated with 20mg/kg of DOX while figures 5.9G and 5.9H represent that of infected 
groups of mice treated with 60mg/kg of DOX. The administration of both doses of 
DOX reduced the extent of inflammation in both bronchioles and alveoli and 
hyperplasia of bronchioles was also lessened. Alveolar spaces were less congested, as 
seen from the images taken under 100X magnification (Arrowheads) and protein 




Figure 5.10 shows histopathological scores of the Hematoxylin and Eosin (H & E) 
stained lung tissue sections, scored by a trained histopathologist, Dr Seet Ju Ee, 
according to the extent of inflammation in the lungs. The scoring system utilised was 
as follows: 0: Normal lungs; 1: Bronchiolitis only, not affecting surrounding alveoli; 
2: Bronchiolitis and peribronchiolar alveolitis; 3: Bronchiolitis and alveolitis affecting 
airspaces away from bronchioles, patchy, <50%; 4: Bronchiolitis and alveolitis 
affecting airspaces away from bronchioles, patchy, >50%; 5: Bronchiolitis and 
alveolitis affecting airspaces away from bronchioles, diffuse,  >50%. The scores for 
all three control groups of uninfected mice were 0, which was expected as the mice 
were not inoculated with virus and no inflammation should be present. The score for 
the infected group of mice treated with water was on average 3.5, which included 
bronchiolitis and rather extensive alveolitis. Upon 20mg/kg and 60mg/kg DOX 
treatment of infected mice, the histopathology scores decreased from 3.5 to 3, which 





































Figure 5.9. Hematoxylin and Eosin staining in formalin-fixed lung tissue sections 
upon doxycycline (DOX) treatment. Representative images of each group were 
taken at 100X magnification (A, C, E) and 400X magnification (B, D, F). A and B: 
Control mice treated with water. C and D: Control mice treated with 20mg/kg DOX; 
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Figure 5.9 (Continued). Hematoxylin and Eosin staining in formalin-fixed lung 
tissue sections upon doxycycline (DOX) treatment. Representative images of each 
group were taken at 100X magnification (G, I, K) and 400X magnification (H, J, L). 
G and H: Infected mice treated with water. I and J: Infected mice treated with 
20mg/kg DOX; K and L: Infected mice treated with 60mg/kg DOX.. Br: Bronchioles. 
* shows protein leakage into the air spaces. Arrows show bronchiolitis. Arrowheads 












































Figure 5.10. Histopathological scores upon doxycycline (DOX) treatment in 
formalin-fixed lung tissue sections. Formalin-fixed lung tissue sections were sent to 
Department of Pathology, National University Hospital for microtome sectioning and 
Hematoxylin and Eosin (H & E) staining. Stained sections were observed under a 
light microscope by a trained histopathologist, Dr Seet Ju Ee, and scored according to 
extent of inflammation in the lungs. Error bars represent SEM of the animals in each 
group (Control: n=4, Control + 20mg/kg DOX: n=4, Control + 60mg/kg DOX: n=4, 
Infected: n=8, Infected + 20mg/kg DOX: n=8, Infected + 60mg/kg DOX: n=8). 0: 
Normal; 1: Bronchiolitis only, not affecting surrounding alveoli; 2: Bronchiolitis and 
peribronchiolar alveolitis; 3: Bronchiolitis and alveolitis affecting airspaces away 
from bronchioles, patchy, <50%; 4: Bronchiolitis and alveolitis affecting airspaces 
away from bronchioles, patchy, >50%; 5: Bronchiolitis and alveolitis affecting 
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5.1.10 Western Blot of T1-α and Thrombomodulin protein levels in BALF 
 
 
To evaluate the effects of doxycycline (DOX) treatment on lung injury upon influenza 
A/Aichi/2/68 (H3N2) P10 virus infection, western blot was done on T1-α and 
thrombomodulin proteins present in the bronchoalveolar lavage fluid (BALF) samples 
obtained from control and infected mice, with or without treatment of DOX. 
Thrombomodulin is a surface protein of vascular endothelial cells and is a marker for 
endothelial damage (Himmelreich et al, 1994). T1-α is a protein expressed in apical 
membrane of type I alveolar epithelial cells and is a marker for epithelial damage 
(McElroy and Kasper  ¸ 2004). With reference to figure 5.11A, our results revealed 
little or no expression of both T1-α and thrombomodulin proteins in the BALF 
samples obtained from control mice in all groups, with or without DOX treatment. 
Influenza virus infection increased protein expressions of both T1-α and 
thrombomodulin proteins in the BALF and upon lower dose DOX treatment at 
20mg/kg, the protein expressions of both proteins were significantly reduced, as 
compared to the infected group treated with water. At higher dose of 60mg/kg DOX 
treatment, no reduction in both endothelial and epithelial markers were observed. 
Densitometric analyses of the bands showed a 1.4 fold reduction and 1.3 fold 
reduction in T1-α and thrombomodulin protein expressions respectively, in BALF 
samples obtained from 20mg/kg DOX treated groups of infected mice, as compared to 






















Figure 5.11. Western blot analysis depicting T1-α and Thrombomodulin (TM) 
protein expression in mice BALF samples upon Doxycycline (DOX) treatment. 
(A) Blots obtained from mice BALF samples. Lanes 1, 2 and 3 represent control 
samples of uninfected mice treated with water, uninfected mice treated with 20mg/kg 
DOX and uninfected mice treated with 60mg/kg DOX respectively; Lanes 4 and 5 
represent infected mice treated with water; Lanes 6 and 7 represent infected mice 
treated with 20mg/kg DOX; Lanes 8 and 9 represent infected mice treated with 
60mg/kg DOX. Pictures are representative of all animals within the group. (B) 
Densitometric analyses of Western blot bands, each expressed as the absolute 
intensity of the band. White bars represent control uninfected mice, black bars 
represent infected mice, light grey bars represent infected samples treated with 
20mg/kg DOX and dark grey bars represent infected samples treated with 60mg/kg 
DOX. Error bars represent SEM of the animals in each group Error bars represent 
SEM of the animals in each group (Control: n=4, Control + 20mg/kg DOX: n=4, 
Control + 60mg/kg DOX: n=4, Infected: n=8, Infected + 20mg/kg DOX: n=8, 
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5.1.11 Blood agar streaking of mice lung homogenates 
Mice lung homogenates from control and infected mice, either with or without 
treatment of doxycycline, were streaked onto blood agar plates to detect for presence 
of secondary bacteria infection due to influenza virus infection of the host. Figure 
5.12 shows the blood agar plates after 48h incubation in 37°c. Panel A shows the 
blood agar streaked with mice lung homogenates from control groups of uninfected 
mice treated with water, 20mg/kg DOX and 60mg/kg DOX while panel B shows 
blood agar streaked with mice lung homogenates from influenza virus-infected mice 
treated with water. Panels C and D represent blood agars streaked with mice lung 
homogenates from influenza virus-infected mice treated with 20mg/kg DOX and 
60mg/kg DOX respectively. There were no colony formation in all groups of mice, 


































Figure 5.12. Blood agar streaking of mice lung homogenates upon doxycycline 
(DOX) treatment. (A) Blood agar streaked with mice lung homogenates from control 
groups of uninfected mice treated with water, 20mg/kg DOX and 60mg/kg DOX. (B) 
Blood agar streaked with mice lung homogenates from influenza virus-infected mice 
treated with water. (C) Blood agar streaked with mice lung homogenates from 
influenza virus-infected mice treated with 20mg/kg DOX. (D) Blood agar streaked 
with mice lung homogenates from influenza virus-infected mice treated with 60mg/kg 
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5.2.1  Influenza as a Public Health Concern  
In the past century alone, Influenza viruses have already been responsible for four 
major pandemics, with the pandemic of 1918 causing deaths in excess of 50 million 
worldwide (Taubenberger and Morens, 2006). Although the latest 2009 H1N1 
pandemic caused far less deaths, it still posed a significant health burden to human 
populations such as that of the United States in just the first few months of circulation 
in terms of years of life lost (Viboud et al, 2010). This thus justifies the need for 
effective vaccine programs to be rolled out to the market to treat the population 
against Influenza infections prophylatically. Current anti-viral strategies and drugs 
such as the use of Tamiflu®, coupled with other prophylaxis, have been able to 
reduce attack rates as demonstrated by computer modelling and simulation (Halder et 
al, 2010). Influenza infections cause pulmonary damage and post-infection sequelae. 
The most clinically apparent is pneumonia, leading to death due to respiratory failure 
after approximately 10 days post-infection. Such progressive respiratory failure has 
been attributed to Acute Respiratory Distress Syndrome (ARDS) and acute lung 
injury in most cases. Pathological analyses have also revealed that 64% of patients 
with ARDS go on to develop pulmonary fibrosis in the convalescent phase (Claas et 
al, 1998; Qiao et al, 2009), which predisposes these patients to risk of secondary 
respiratory failure within a few years. There is hence a need to develop an effective 





5.2.2 Use of doxycycline (MMP inhibitor) in alleviating pulmonary conditions 
Excessive neutrophil recruitment and activation of matrix metalloproteinases 
(MMPs), particularly gelatinases MMP-2 and MMP-9, upon influenza virus infection 
suggests their possible implication in acute lung injury (ALI) or acute respiratory 
distress syndrome (ARDS), in influenza virus infection. Hence, we hypothesise that 
inhibition of MMP activity may reduce immunopathology and might be an important 
approach for the amelioration of influenza-induced host lung injury. MMP inhibitors 
have been most extensively researched on in cancer therapy due to the immense role 
MMPs play in cancer development and metastasis but in recent years, more begin to 
explore the therapeutic potential of MMP inhibitors in other conditions such as 
cardiac diseases, skin diseases and pulmonary diseases (Fingleton, 2007; Overall and 
Lόpez-Otín, 2002). MMP inhibitors have been shown to be an effective therapeutic 
agent in animal models whereby they can prevent pathological changes of 
emphysema and ARDS, conditions commonly observed in influenza virus-infected 
patients (Elkington and Friedland, 2006). Carney et al, 2001 demonstrated the 
prophylactic use of a chemically modified tetracycline, COL-3, in a porcine model of 
ARDS and this combined MMP and elastase inhibitor effectively prevented the 
development of ARDS. Furthermore, synthetic MMP inhibitors have been shown to 
have a therapeutic role in resolution of lung damages in mice undergoing bleomycin-
induced pulmonary fibrosis and rats exhibiting ARDS condition (Corbel et al, 2001; 




Doxycycline is a non-specific MMP inhibitor administration and its role in MMP 
inhibition, in particular that of MMP-2 and MMP-9, has been extensively studied. It 
has been shown to have protective roles via their MMP inhibitory actions in various 
pulmonary conditions such as toluene diisocyanate induced asthma, 
lipopolysaccharide-induced or gut ischemia-induced acute lung injury and pulmonary 
fibrosis. In these studies, administration of doxycycline resulted in decrease in 
inflammation, in particular neutrophil numbers, accompanied by decrease in 
gelatinase expression. The animal lungs show significantly reduced pulmonary 
injuries and pathologic lesions (Fujita et al, 2007; Hoyt et al, 2006; Lee et al, 2004; 
Liu et al  ¸ 2006). These previous studies thus serve as potential insights into the 
exploration of doxycycline‘s role as a MMP inhibitor in abrogating the effects of 
influenza-induced lung injury and damage and its prevention of ALI or ARDS, 
common post-infection seqeulae in influenza infections. 
 
5.2.3 Doxycycline treatment of mice infected with mouse-adapted Influenza 
A/Aichi/2/68 P10 (H3N2) virus     
Doxycycline treatment of mice infected with Influenza A/Aichi/2/68 P10 (H3N2) 
virus decreased gelatinases MMP-2 and MMP-9 expressions and activities in BALF 
samples, as determined by both western blot and gelatinase zymography. This was 
depicted by figures 5.2 and 5.3 respectively. This is congruent with findings from 
other studies in which both gelatinases were reduced upon doxycycline treatment in 
rat studies or human patients with abdominal aortic aneurysm (Curci et al, 2000; 
Petrinec et al, 1996). Furthermore, Lee et al, 2004 and Fujita et al, 2006 has shown 
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that doxycycline reduces MMP-9 expression in asthma and pulmonary fibrosis model 
respectively. With the current evidence that doxycycline inhibits activity of 
gelatinases, we cannot however, exclude the importance of the inhibition of other 
MMPs by this drug. Doxycycline has been known to preferentially inhibit MMP-2, 
MMP-9 and MMP-8 activities and is a much weaker inhibitor of MMP-1 and in this 
study, we focused mainly on its effects on MMP-2 and MMP-9 (Cena et al, 2010). 
The mechanisms by which doxycycline inhibits MMP activities are not clearly 
defined but the most likely mechanism would be the ability of the drug to chelate 




 which are associated with the MMP enzyme. This 
renders the active site inaccessible and blocks activation of the proenzymes (Smith 
and Cook, 2004). It has also been suggested that doxycycline inhibits synthesis of 
MMPs indirectly through the inhibition of secretion of the proinflammatory cytokine 
interleukin-1 (IL-1) while Lee et al, 2004 and Esteve et al, 2002 reported that the 
phophatidylinositol 3-kinase is likely involved in the signaling cascade to inhibit 
MMP-9 gene transcription (Solomon et al, 2000).  
 
When total inflammatory cell counts and differential cell counts were done on BALF 
samples, the data showed that doxycycline as an anti-inflammatory drug worked as 
planned and trypan blue staining revealed a reduction in migration of total 
inflammatory cells into the airways following influenza virus infection, shown in 
figure 5.4. This decrease in inflammation is not dose-dependant statistically. 
Differential cell counts showed decreases in macrophages, neutrophils and 
lymphocytes upon doxycycline treatment and the neutrophil data is further supported 
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by MPO assay, in which the activities of these polymorphonuclear leukocytes were 
decreased upon drug treatment, shown in figure 5.6, but this decrease is not dose-
dependant. Furthermore, histopathology slides of mice lungs showed a similar trend 
of decrease in inflammatory infiltration and from figure 5.10, it was observed that the 
drug reduced the extent of inflammation in influenza infected lungs. A study from Lee 
et al, 2004 reported that the migration of total inflammatory cells, lymphocytes, 
neutrophils and eosinophils into the airspaces was strongly inhibited by doxycycline 
in a murine model of toluene diisocyanate-induced asthma. The reduction of airway 
inflammation was shown to be through the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway and this might be a possible mechanism in which doxycycline decreases 
inflammation in influenza-infected mice since PI3K and its downstream effector 
protein kinase Akt is one of the signaling mediators activated by influenza viruses 
which results in inflammation (Ehrhardt and Ludwig, 2009). The decrease in 
gelatinase expression observed upon doxycycline treatment has an abrogating effect 
on inflammation since MMP-2 and MMP-9 can cleave and activate pro-inflammatory 
cytokines interleukin-1 (IL-1) and tumor necrosis factor (TNF), which are expressed 
by neutrophils and function as potent chemoattractants for further neutrophil 
recruitment (Parks et al, 2004; Witko-Sarsat et al, 2000). Furthermore, gelatinases aid 
in migration of leukocytes from the circulation to the site of injury through 
degradation of the basement membrane and MMP-9 has been reported to generate a 
tripeptide PGP which is chemotactic for neutrophils (Gaggar et al, 2008). Inhibition 
of gelatinases by doxycycline would thus lead to reduced migration of inflammatory 
cells, especially neutrophils, through the basement membrane and into the airspaces. 
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BALF proteins were subjected to the Lowry protein estimation assay and from figure 
5.8, it was observed that protein concentrations from the BALF supernatant were 
more elevated in the infected group of mice treated with water as compared to the 
doxycycline treated groups. The BALF protein concentrations collected from the mice 
would point to the extent of damage in the airway epithelium and endothelium, which 
results in the leakage of proteins into the airspaces. The fact that BALF protein 
concentrations were significantly elevated in the water treated group of infected mice 
would validate the increased inflammatory reponse observed in this group of mice 
leading to the leakage of proteins, shown in histopathology slides in figure 5.9D,  
from the adjacent damaged capillaries and necrotic cells into the air spaces. Epithelial 
and endothelial damage which results in protein leakage is demonstrated by western 
blot analysis of T1-α and thrombomodulin proteins present in mice BALF samples 
respectively, and gives an indication of the extent of host lung injury upon influenza 
infection. Thrombomodulin is a surface protein of vascular endothelial cells and is a 
marker for endothelial damage while T1-α is a protein expressed in apical membrane 
of type I alveolar epithelial cells and is a marker for epithelial damage (Himmelreich 
et al, 1994; McElroy and Kasper, 2004). Figure 5.11 shows a marked increase in both 
T1-α and thrombomodulin markers in BALF samples collected from influenza 
infected mice treated with water, indicating damaged epithelium and endothelium 
which contributes to increased protein leakage observed in these mice, together with 
exacerbated host lung injury. The alveolar architecture was also damaged and 
hyperplasia of the bronchioles was seen by the thickened bronchiol columnar 
epithelial cells, indicative of cell proliferation in response to damage caused by the 
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influenza infection. This would have rendered the animals extremely hypoxic and is 
indicative of acute lung injury which would have led to ARDS in the mice. The 
administration of 20mg/kg and 60mg/kg doxycycline in influenza infected mice 
reduced the extent of inflammation in both bronchioles and alveoli and this was 
accompanied by a significant dose-dependant reduction in protein leakage into the 
airspaces, supported by BALF protein estimation and histopathology slides, displayed 
in figures 5.8 and 5.9 respectively. When we evaluated epithelial and endothelial 
damage by western blot, infected mice treated with 20mg/kg doxcycyline showed 
marked reduction in T1-α and thrombomodulin protein expressions in mice BALF 
samples compared to water-treated infected mice, indicating less lung injury, which 
correlates well with the decreased inflammation and protein leakage into the 
airspaces. Reduction in inflammation, especially neutrophils, would limit release of 
terminal effectors such as neutrophil elastases, matrix metalloproteinases and oxygen 
radical species which could lead to damage of both pulmonary endothelial and 
epithelial cells, and prevent disruption of capillary-alveolar barrier and leakage of 
proteinaceous fluid into the alveolar space and airways. The reduction of MMP-2 and 
MMP-9 activities by doxycycline further diminished their pathological roles in 
degradation of basement membrane which would otherwise contribute to pulmonary 
damage. At a higher dose of 60mg/kg doxycycline treatment, however, no reduction 
in both endothelial and epithelial markers was observed though the extent of 
inflammation was decreased. When we measured virus titre by plaque assay, depicted 
by figure 5.7, we noticed that virus titre for the 60mg/kg doxcycyline treated group of 
infected mice was increased by four times, as compared to the water-treated group. A 
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reasonable explanation would be that the higher dose of doxycycline treatment 
reduced macrophage and neutrophil numbers substantially, thus impairing viral 
clearance and the increased virus present would have detrimental effects on the 
epithelium and endothelium directly, resulting in damage to the airway and vascular 
linings. Influenza virus infects alveolar epithelial and vascular endothelial cells 
directly and lead to cell damage induced by downregulation of host cell protein 
synthesis and apoptosis (Behrens and Stoll, 2006; Chan et al, 2009; Sumikoshi et al, 
2008). Apoptosis in influenza-infected cells is mediated by Fas-mediated pathway and 
Fas-independent signals such as formation of FADD/caspase-8 complex by protein 
kinase R and activation of latent transforming growth factor by viral neuraminidase 
cleavage (Behrens and Stoll, 2006; Brydon et al  ¸2003).  
 
Doxycycline treatment of mice, however, did not improve the weights of influenza-
infected mice and these mice lost as much or more weight than water-treated infected 
mice alone, as shown in figure 5.1. This was surprising to us since recently, Ryan et 
al, 2009 observed that when influenza virus-infected mice were given prior treatment 
to 60mg/kg doxycycline, mice had less body weight loss compared to mice receiving 
no drug. However, this beneficial effect was dose-dependent since mice given 
20mg/kg doxycycline showed increased mortality compared to water-treated group. In 
our study, the weight loss observed in doxycycline-treated group might be attributed 
to the gastrointestinal properties of doxycycline, including anorexia, nausea, vomiting 
and diarrhea, which have been documented as possible adverse effects in patients by 
 134 
 
the U.S Food and Drug Administration (FDA, 2010). The mice infected with 
influenza virus would already be suffering from loss of appetite due to effects of the 
virus and doxycycline administration would render the animals further loss in appetite 
due to potential adverse effects. Mice which were not inoculated with influenza virus 
but have been fed doxycycline showed no weight loss and this proved to us that 
doxycycline did not have any cytotoxic effects on the animals, which was further 
confirmed by the histopathologist‘s report stating that gastrointestinal organs such as 
the stomach and liver showed normal appearances. Thus, the drastic loss of weights in 
infected mice treated with doxycycline is not likely to be toxic effects on other 
organs, but might most likely be due to their resistance to feed and drink. In influenza 
virus infections, secondary bacterial superinfections are common and are usually the 
cause of serious morbidity and mortality, especially in elderly adults (Behrens and 
Stoll, 2006). To eliminate the possibility that in our study, secondary bacterial 
infection due to influenza virus infection contributed to host lung injury and that 
doxycycline, being an antibiotic, cleared the bacteria to alleviate host lung injury, we 
streaked lung homogenates onto blood agar plates to detect for presence of secondary 
bacteria infection due to influenza virus infection of the host. From figure 5.12, 
absence of bacteria was observed in lung homogenates of mice in all the groups and 
this indicated that doxycycline alleviated influenza-induced host lung injury through 
mechanisms independent of its antibacterial properties and possibly through its 




5.3 CONCLUSION  
In this study, we have hypothesized that the use and administration of doxycycline to 
influenza-infected mice would ameliorate pulmonary damage similar to other lung 
injury models. Judging from our data, we have shown that a low dose of doxycycline 
successfully reduces inflammatory cell infiltration and gelatinase activities, which 
results in lessened endothelial and epithelial injury, accompanied by decreased protein 
leakage into the airspaces. This finding is crucial as MMPs and inflammation have 
been regarded as important components to initiate the progression of influenza host 
lung injury into more severe conditions such as ARDS. The role of doxycycline in 
alleviating influenza-induced host acute lung injury is depicted in figure 5.13. 
However, a higher dose of the drug did not help the pulmonary injuries in mice as the 
substantial reduction in inflammation resulted in inefficient viral clearance and 
eventually, high virus load which had direct detrimental effects on the host cells. This 
was the first indicator that doxycycline treatment in influenza virus infection was 
dose-dependant and future experiments combining doxycycline treatment with 
existing antiviral strategies such as Tamiflu® might have beneficial results in 
preventing mortality and morbidity in the Influenza pneumonitis murine model. 
Survival studies in murine models could be done to further substantiate the claims of 
the protective role of doxycyline in influenza infection by assessing if the drug could 
reduce mortality of mice. Furthermore, future work such as the use of more specific 
MMP-2 and MMP-9 inhibitors would provide greater insights into the roles of these 
gelatinases in influenza-induced host lung injury since doxycycline is considered a 
broad spectrum MMP inhibitor. In addition, we could evaluate the effects of 
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doxycycline on gelatinase expression in individual cell types by treating influenza-
infected LA-4 alveolar epithelial cells or MPRO neutrophil cells with the drug. These 
in vitro studies might provide us more information on the cell types which are 
responsible for producing gelatinases during influenza virus infection and specific 
cellular targets for potential therapeutic intervention.  
 
In conclusion, based on findings from the series of experiments conducted in this 
study, administration of doxycycline as an anti-inflammatory drug and MMP inhibitor 
proved to be a potential therapeutic agent in mice when infected with Influenza. It 
would be beneficial to supplement doxcycyline with current anti-viral drugs regimens, 
such as oseltamivir, to reduce the viral load and consequently, the virus-associated 
inflammatory processes and pulmonary injury. This would hence serve as a potential 
target for clinical studies on humans to ameliorate pulmonary damage in influenza 
patients. This is especially salient with the threat of the highly pathogenic and virulent 
H5N1 Avian Influenza looming over the horizon, exploration and development of 
treatment strategies such as with existing approved drugs like doxycycline, before 
vaccines can be developed would be largely beneficial in reducing the impacts of 








































Figure 5.13. Schematic diagram of contribution of doxycycline in alleviating 
influenza host lung injury. Red crosses represent inhibitory effects of doxycycline 
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CHAPTER 7: APPENDICES 
 
 







Con R1 19.21 24.13 4.92 5.305       
Con R1 19.44 24.44 5         
Con R2 17.95 23.47 5.52         
Con R2 17.87 23.65 5.78         
INF B1 16.55 22.31 5.76 5.809 0.504 0.705149 -1.41814 
INF B1 16.45 22.21 5.76         
INF B2 18.84 24.97 6.13         
INF B2 18.99 25.03 6.04         
INF B3 19.77 24.93 5.16         
INF B3 19.61 25.25 5.64         
INF B4 15.74 21.94 6.2         
INF B4 15.72 21.67 5.95         
INF B5 23.48 29.16 5.68         
INF B5 23.43 29.2 5.77         
 
Table 7.1. Ct values obtained from Real-time PCR of MMP-2 gene for control uninfected and influenza virus-infected BALB/c mice on 
day 3 post-infection timepoint (in vivo experiment). Data above was analyzed by real-time PCR. Gene expression of MMP-2 was normalized 
to gene expression levels of housekeeping gene β-actin. Graph summarizing the fold change of gene expression levels of the MMP-2 gene is 














Con R3 16.82 22.03 5.21 5.488333 
   Con R3 16.72 22.42 5.7 
    Con R4 19.73 25.65 5.92 
    Con R4 19.8 25.55 5.75 
    Con R5 17.99 23.23 5.24 
    Con R5 18.12 23.23 5.11 
    INF RB1 22.73 27.76 5.03 6.436 0.947667 0.51847 -1.92875 
INF RB1 22.66 28.03 5.37 
    INF RB2 14.76 20.9 6.14 
    INF RB2 14.77 20.94 6.17 
    INF RB3 18.19 23.94 5.75 
    INF RB3 18.16 24.14 5.98 
    INF RB4 27.78 35.36 7.58 
    INF RB4 27.8 34.31 6.51 
    INF RB5 27.46 36 8.54 
    INF RB5 27.14 34.43 7.29 
     
Table 7.2. Ct values obtained from Real-time PCR of MMP-2 gene for control uninfected and influenza virus-infected BALB/c mice on 
day 6 post-infection timepoint (in vivo experiment). Data above was analyzed by real-time PCR. Gene expression of MMP-2 was normalized 
to gene expression levels of housekeeping gene β-actin. Graph summarizing the fold change of gene expression levels of the MMP-2 gene is 














Con R1 19.21 25.13 5.92 6.3725 
   Con R1 19.44 25.02 5.58 
    Con R2 17.95 24.92 6.97 
    Con R2 17.87 24.89 7.02 
    INF B1 16.55 23.61 7.06 6 -0.3725 1.294594249 1.295 
INF B1 16.45 23.64 7.19 
    INF B2 18.84 25.74 6.9 
    INF B2 18.99 25.68 6.69 
    INF B3 19.77 25.49 5.72 
    INF B3 19.61 25.54 5.93 
    INF B4 15.74 23.62 7.88 
    INF B4 15.72 23.67 7.95 
    INF B5 23.48 25.72 2.24 
    INF B5 23.43 25.87 2.44 
     
 
Table 7.3. Ct values obtained from Real-time PCR of MMP-9 gene for control uninfected and influenza virus-infected BALB/c mice on 
day 3 post-infection timepoint (in vivo experiment). Data above was analyzed by real-time PCR. Gene expression of MMP-9 was normalized 
to gene expression levels of housekeeping gene β-actin. Graph summarizing the fold change of gene expression levels of the MMP-9 gene is 
























Table 7.4. Ct values obtained from Real-time PCR of MMP-9 gene for control uninfected and influenza virus-infected BALB/c mice on 
day 6 post-infection timepoint (in vivo experiment). Data above was analyzed by real-time PCR. Gene expression of MMP-9 was normalized 
to gene expression levels of housekeeping gene β-actin. Graph summarizing the fold change of gene expression levels of the MMP-9 gene is 












Con R3 16.82 24.03 7.21 6.911667 
   Con R3 16.72 24.02 7.3 
    Con R4 19.73 25.97 6.24 
    Con R4 19.8 26.1 6.3 
    Con R5 17.99 25.25 7.26 
    Con R5 18.12 25.28 7.16 
    INF RB1 22.73 28.01 5.28 3.15875 -3.75292 13.48157 13.48157 
INF RB1 22.66 28 5.34 
    INF RB3 18.19 24.87 6.68 
    INF RB3 18.16 25 6.84 
    INF RB4 27.78 28.47 0.69 
    INF RB4 27.8 28.71 0.91 
    INF RB5 27.46 26.94 -0.52 
    INF RB5 27.14 27.19 0.05 









% Relative to 
Control 
Con 0h 178.97 2444 437402.68 
697687.37 100 Con 0h 236.07 4058 957972.06 
Con 12h 163.06 2665 434554.9 
774763.01 100 Con 12h 233.16 4782 1114971.12 
Con 24h 173.82 2625 456277.5 
690427.71 100 Con 24h 231.84 3988 924577.92 
Con 48h 178.59 2289 408792.51 
756005.265 100 Con 48h 226.58 4869 1103218.02 
Inf 0h 156.84 2300 360732 
686972.685 98.46425699 Inf 0h 229.91 4407 1013213.37 
Inf 12h 186.35 3414 636198.9 
1002985.4 129.4570581 Inf 12h 239.89 5710 1369771.9 
Inf 24h 186.05 3435 639081.75 
1003532.625 145.3494132 Inf 24h 240.25 5694 1367983.5 
Inf 48h 186.51 3804 709484.04 
1168821.72 154.6049709 Inf 48h 239.4 6801 1628159.4 
 
Table 7.5. Absolute intensities of bands obtained from densitometric analyses of MMP-2 Western blot bands for control uninfected and 
influenza virus-infected LA-4 cells (in vitro experiment). Graph depicting percentage of MMP-2 band desitometries in infected cells 













% Relative to 
Control 
Ctrl 0h 11.98 101 1209.98 
1191.565 100 Ctrl 0h 11.85 99 1173.15 
Ctrl 12h 12.98 99 1285.02 
1051.335 100 Ctrl 12h 11.85 69 817.65 
Ctrl 24h 99.2 522 51782.4 
57890.525 100 Ctrl 24h 116.15 551 63998.65 
Ctrl 48h 199.3 313 62380.9 
71490.71 100 Ctrl 48h 188.76 427 80600.52 
Inf 0h 11.98 101 1209.98 
1191.565 100 Inf 0h 11.85 99 1173.15 
Inf 12h 12.98 89 1155.22 
1007.135 95.7958215 Inf 12h 12.45 69 859.05 
Inf 24h 54.38 647 35183.86 
50017.93 86.40089203 Inf 24h 130.75 496 64852 
Inf 48h 159.98 856 136942.88 
142966.315 199.9788714 Inf 48h 152.81 975 148989.75 
 
Table 7.6. Absolute intensities of bands obtained from densitometric analyses of MMP-9 Western blot bands for control uninfected and 
influenza virus-infected LA-4 cells (in vitro experiment). Graph depicting percentage of MMP-9 band desitometries in infected cells 




























Table 7.7. Absolute intensities of bands obtained from densitometric analyses of MMP-2 gelatinase zymography bands for control 
uninfected and influenza virus-infected LA-4 cells (in vitro experiment). Graph depicting percentage of MMP-2 band desitometries in 
infected cells expressed relative to control cells at 0h, 12h, 24h and 48h timepoints are shown in figure 4.16. 
 
 





% Relative to 
Control 
Ctrl 0h 7.31 265 1937.15 
4862.125 100 Ctrl 0h 7.71 1010 7787.1 
Ctrl 12h 23.58 595 14030.1 
31403.56 100 Ctrl 12h 19.82 2461 48777.02 
Ctrl 24h 11.78 284 3345.52 
24834.69 100 Ctrl 24h 21.82 2123 46323.86 
Ctrl 48h 7.93 176 1395.68 
14198.36 100 Ctrl 48h 20.12 1342 27001.04 
Inf 0h 7.31 265 1937.15 
4862.125 100 Inf 0h 7.71 1010 7787.1 
Inf 12h 15.51 501 7770.51 
28929.18 92.12070224 Inf 12h 19.65 2549 50087.85 
Inf 24h 13.83 993 13733.19 
37562.19 151.2488781 Inf 24h 19.81 3099 61391.19 
Inf 48h 11.51 230 2647.3 



























Table 7.8. Absolute intensities of bands obtained from densitometric analyses of MMP-9 gelatinase zymography bands for control 
uninfected and influenza virus-infected LA-4 cells (in vitro experiment). Graph depicting percentage of MMP-9 band desitometries in 
infected cells expressed relative to control cells at 0h, 12h, 24h and 48h timepoints are shown in figure 4.16. 





% Relative to 
Control 
Ctrl 0h 14.76 963 14213.88 
8450.465 100 Ctrl 0h 8.81 305 2687.05 
Ctrl 12h 124.42 1142 142087.64 
79727.42 100 Ctrl 12h 25.54 680 17367.2 
Ctrl 24h 81.41 1037 84422.17 
44488.635 100 Ctrl 24h 9.02 505 4555.1 
Ctrl 48h 42.06 911 38316.66 
20637.48 100 Ctrl 48h 10.38 285 2958.3 
Inf 0h 39.08 703 27473.24 
14898.615 176.3052684 Inf 0h 7.57 307 2323.99 
Inf 12h 173.11 1543 267108.73 
142750.365 179.0480176 Inf 12h 24.2 760 18392 
Inf 24h 125.15 1194 149429.1 
83217.51 187.0534126 Inf 24h 19.96 852 17005.92 
Inf 48h 127.95 1361 174139.95 
91148.595 441.6653341 Inf 48h 17.43 468 8157.24 
